CA3129790A1 - Seaweed-derived cosmetic compositions - Google Patents
Seaweed-derived cosmetic compositions Download PDFInfo
- Publication number
- CA3129790A1 CA3129790A1 CA3129790A CA3129790A CA3129790A1 CA 3129790 A1 CA3129790 A1 CA 3129790A1 CA 3129790 A CA3129790 A CA 3129790A CA 3129790 A CA3129790 A CA 3129790A CA 3129790 A1 CA3129790 A1 CA 3129790A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- amount
- composition includes
- acid
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 518
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 241001474374 Blennius Species 0.000 title description 18
- 239000000284 extract Substances 0.000 claims abstract description 30
- 229920000855 Fucoidan Polymers 0.000 claims abstract description 28
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 27
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000004094 surface-active agent Substances 0.000 claims description 27
- 239000011731 tocotrienol Substances 0.000 claims description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 230000000475 sunscreen effect Effects 0.000 claims description 17
- 239000000516 sunscreening agent Substances 0.000 claims description 17
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 16
- 241000196252 Ulva Species 0.000 claims description 16
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 229930003802 tocotrienol Natural products 0.000 claims description 16
- 235000019148 tocotrienols Nutrition 0.000 claims description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 15
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 15
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 15
- 229940075529 glyceryl stearate Drugs 0.000 claims description 15
- 239000005332 obsidian Substances 0.000 claims description 15
- 229960005323 phenoxyethanol Drugs 0.000 claims description 15
- 229910052613 tourmaline Inorganic materials 0.000 claims description 15
- 229940070527 tourmaline Drugs 0.000 claims description 15
- 239000011032 tourmaline Substances 0.000 claims description 15
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 14
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 14
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 14
- 229940075582 sorbic acid Drugs 0.000 claims description 14
- 235000010199 sorbic acid Nutrition 0.000 claims description 14
- 239000004334 sorbic acid Substances 0.000 claims description 14
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 244000133098 Echinacea angustifolia Species 0.000 claims description 13
- 235000011399 aloe vera Nutrition 0.000 claims description 13
- 235000014134 echinacea Nutrition 0.000 claims description 13
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 13
- -1 phycocolloid Substances 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 244000042664 Matricaria chamomilla Species 0.000 claims description 12
- 235000021355 Stearic acid Nutrition 0.000 claims description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000008117 stearic acid Substances 0.000 claims description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 11
- 235000013793 astaxanthin Nutrition 0.000 claims description 11
- 239000001168 astaxanthin Substances 0.000 claims description 11
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 11
- 229940022405 astaxanthin Drugs 0.000 claims description 11
- 229940073669 ceteareth 20 Drugs 0.000 claims description 11
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- 244000052707 Camellia sinensis Species 0.000 claims description 10
- 235000006468 Thea sinensis Nutrition 0.000 claims description 10
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 10
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 241000590031 Alteromonas Species 0.000 claims description 9
- 244000163122 Curcuma domestica Species 0.000 claims description 9
- 244000194101 Ginkgo biloba Species 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 9
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 9
- 235000003373 curcuma longa Nutrition 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 8
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 8
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 8
- 229960002061 ergocalciferol Drugs 0.000 claims description 8
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 235000020944 retinol Nutrition 0.000 claims description 8
- 229960003471 retinol Drugs 0.000 claims description 8
- 239000011607 retinol Substances 0.000 claims description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 8
- 235000001892 vitamin D2 Nutrition 0.000 claims description 8
- 239000011653 vitamin D2 Substances 0.000 claims description 8
- VDLQUOJGOLARHR-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxybenzoic acid Chemical compound OCC(O)=O.OC(=O)C1=CC=CC=C1O VDLQUOJGOLARHR-UHFFFAOYSA-N 0.000 claims description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 7
- 240000004371 Panax ginseng Species 0.000 claims description 7
- 235000002789 Panax ginseng Nutrition 0.000 claims description 7
- 241000199919 Phaeophyceae Species 0.000 claims description 7
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims description 7
- 229960000458 allantoin Drugs 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 229930007845 β-thujaplicin Natural products 0.000 claims description 7
- SGVYKUFIHHTIFL-UHFFFAOYSA-N 2-methylnonane Chemical compound CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 6
- 244000146462 Centella asiatica Species 0.000 claims description 6
- 235000004032 Centella asiatica Nutrition 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 241000202807 Glycyrrhiza Species 0.000 claims description 6
- 125000003047 N-acetyl group Chemical group 0.000 claims description 6
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- 241001261506 Undaria pinnatifida Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000017700 silymarin Nutrition 0.000 claims description 6
- 229960004245 silymarin Drugs 0.000 claims description 6
- 235000013976 turmeric Nutrition 0.000 claims description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 5
- 239000005995 Aluminium silicate Substances 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 5
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 5
- 241000219053 Rumex Species 0.000 claims description 5
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 5
- 235000012211 aluminium silicate Nutrition 0.000 claims description 5
- 239000000440 bentonite Substances 0.000 claims description 5
- 229910000278 bentonite Inorganic materials 0.000 claims description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 5
- 235000001785 ferulic acid Nutrition 0.000 claims description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 5
- 229940114124 ferulic acid Drugs 0.000 claims description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 claims description 5
- 239000003961 penetration enhancing agent Substances 0.000 claims description 5
- 231100000435 percutaneous penetration Toxicity 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 5
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 claims description 5
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 244000144927 Aloe barbadensis Species 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 4
- 241000196222 Codium fragile Species 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 241001512722 Ecklonia cava Species 0.000 claims description 4
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 4
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 4
- 229920002079 Ellagic acid Polymers 0.000 claims description 4
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical group OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 4
- 229960001009 acetylcarnitine Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 229960002852 ellagic acid Drugs 0.000 claims description 4
- 235000004132 ellagic acid Nutrition 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical group CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 244000208874 Althaea officinalis Species 0.000 claims description 3
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 3
- 241000086254 Arnica montana Species 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018062 Boswellia Nutrition 0.000 claims description 3
- 240000007551 Boswellia serrata Species 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 235000003880 Calendula Nutrition 0.000 claims description 3
- 240000001432 Calendula officinalis Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 241000227752 Chaetoceros Species 0.000 claims description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 3
- 244000241235 Citrullus lanatus Species 0.000 claims description 3
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical group C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 241000227647 Fucus vesiculosus Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 3
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 235000011430 Malus pumila Nutrition 0.000 claims description 3
- 235000015103 Malus silvestris Nutrition 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 241000206609 Porphyra Species 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 3
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 241000320380 Silybum Species 0.000 claims description 3
- 235000010841 Silybum marianum Nutrition 0.000 claims description 3
- 241000206733 Skeletonema Species 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 241001491691 Thalassiosira Species 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical group 0.000 claims description 3
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 claims description 3
- 229940007697 benzyl pca Drugs 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 150000001789 chalcones Chemical class 0.000 claims description 3
- 235000005513 chalcones Nutrition 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229940080421 coco glucoside Drugs 0.000 claims description 3
- 235000001671 coumarin Nutrition 0.000 claims description 3
- 229960000956 coumarin Drugs 0.000 claims description 3
- 229940086555 cyclomethicone Drugs 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000019314 gum ghatti Nutrition 0.000 claims description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 3
- 229940091173 hydantoin Drugs 0.000 claims description 3
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 3
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical group CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 235000001035 marshmallow Nutrition 0.000 claims description 3
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical group CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 3
- 239000003883 ointment base Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000012165 plant wax Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920001083 polybutene Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 229920001592 potato starch Polymers 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 230000002087 whitening effect Effects 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- 241000206572 Rhodophyta Species 0.000 claims description 2
- 229930182558 Sterol Natural products 0.000 claims description 2
- 235000009392 Vitis Nutrition 0.000 claims description 2
- 241000219095 Vitis Species 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 125000003147 glycosyl group Chemical group 0.000 claims description 2
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 150000003432 sterols Chemical class 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000062387 Glycine soja Species 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 101
- 229940024606 amino acid Drugs 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 42
- 238000009472 formulation Methods 0.000 description 37
- 238000000034 method Methods 0.000 description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 208000002874 Acne Vulgaris Diseases 0.000 description 10
- 206010000496 acne Diseases 0.000 description 10
- 239000006286 aqueous extract Substances 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 10
- 241001116389 Aloe Species 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- 229960004274 stearic acid Drugs 0.000 description 8
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000008240 homogeneous mixture Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 240000006365 Vitis vinifera Species 0.000 description 5
- 235000014787 Vitis vinifera Nutrition 0.000 description 5
- 235000002532 grape seed extract Nutrition 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 5
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- UBKBVPONTPMQQW-UHFFFAOYSA-N azane;2-hydroxyacetic acid Chemical compound [NH4+].OCC([O-])=O UBKBVPONTPMQQW-UHFFFAOYSA-N 0.000 description 4
- 235000019994 cava Nutrition 0.000 description 4
- 239000001540 sodium lactate Substances 0.000 description 4
- 229940005581 sodium lactate Drugs 0.000 description 4
- 235000011088 sodium lactate Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000167550 Centella Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229940075495 isopropyl palmitate Drugs 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 150000003870 salicylic acids Chemical class 0.000 description 3
- 230000037393 skin firmness Effects 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229940090972 beta-thujaplicin Drugs 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 229940118127 fucus vesiculosus extract Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- 229940055619 selenocysteine Drugs 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001466460 Alveolata Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- 241000199900 Laminariales Species 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000119236 Rhizaria Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: an amount or form of fucoidan, an amount or form of beta glucan; and an amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance of the skin is improved.
Description
SEAWEED-DERIVED COSMETIC COMPOSITIONS
BACKGROUND OF THE INVENTION
1. Field of Invention The present invention relates generally to a cosmetic composition and more particularly to a cosmetic composition containing seaweed for application to skin to improve the appearance of the skin.
BACKGROUND OF THE INVENTION
1. Field of Invention The present invention relates generally to a cosmetic composition and more particularly to a cosmetic composition containing seaweed for application to skin to improve the appearance of the skin.
2. Description of Related Art The skin is one of the largest organs in the body. Skin is comprised of three main layers: the epidermis, the dermis and subcutaneous layers. At the outermost part of the epidermis, a layer of dead cells forms what is known as a stratum comeum layer. The dermis is the middle layer of skin and is comprised of arrangements of collagen fibres, which surround many specialized cells and structures. The innermost layer of the skin is the subcutaneous layer, often called the sub-dermis. The subcutaneous layer is comprised largely of fat and connective tissue and houses larger blood vessels and nerves. Elastin may be found in all layers of the skin, but is most prominent in the dermis layer.
The condition and appearance of the skin is a major concern to most people.
Enhancing the appearance of the skin is of significant interest for many people. The appearance of the skin can be affected by many sources including environmental conditions such as sun exposure, building heating and air conditioning, and air pollution can accelerate deterioration of the condition and appearance of skin.
Additionally, certain diseases can affect the appearance of the skin. Deterioration of the appearance of the skin may include, but is not limited to, wrinkles, loss of firmness and elasticity of the skin, age spots, discolorations, and dryness. In addition, individual factors such as diet, stress, age and genetics may affect the appearance of the skin.
Various compositions and methods for manipulating the appearance of the skin have been reported. For example, international patent application, published under number WO/2004/100889, describes anti-ageing agents, including 3,3'-thiodipropionic acid or derivatives thereof for improving the aesthetic appearance of skin.
Another method of manipulating the quality of the skin is cosmetic surgery. It has been reported Date Recue/Date Received 2021-09-02 that seaweed extracts can be incorporated in compositions for use on the skin (see, for e.g., United States patent application 2004/0219124).
SUMMARY OF THE INVENTION
In accordance with one aspect of the invention there is provided a cosmetic composition for applying to skin. The composition includes a liquid, and dispersed in the liquid an amount of fucoidan, an amount of beta glucan, and an amount of a marine extract, wherein the cosmetic composition improves the appearance of the skin to which the composition is applied.
The composition may further include water as the liquid. The composition may further include the liquid being a glycolic acid-salicylic acid solution. The composition may further include the liquid being water and a glycolic acid-salicylic acid solution. The composition may further include the marine extract being any one or more of a green seaweed, a brown seaweed, an exopolysaccharide, or an algae. The composition may further include the marine extract being Ulva lactuta, Alteromonas maclodeii, Astaxanthin, or EckIonia cava.
In another aspect of the invention, the composition may include an amount of tourmaline. In another aspect of the invention, the composition may include an amount of volcanic obsidian. In another aspect of the invention, the composition may include an amount of Aloe barbadensis. In another aspect of the invention, the composition may include an amount of hydrolyzed pearl nacre. In another aspect of the invention, the composition may include an amount of chitosan. In another aspect of the invention, the composition may include an amount of a phospholipid.
In accordance with another aspect of the invention, the composition may include an amount of glyceryl stearate. In another aspect of the invention, the composition may include an amount of stearic acid. In another aspect of the invention, the composition may include an amount of cetearyl alcohol. In another aspect of the invention, the composition may include an amount of ceteareth 20. In another aspect of the invention, the composition may include an amount of isopropyl palmitate. In another aspect of the invention, the composition may include an amount of ascorbyl polypeptide. In another aspect of the invention, the composition may include an amount of tocotrienol.
In another aspect of the invention, the composition may include an amount of tocopheryl acetate. In Date Recue/Date Received 2021-09-02
The condition and appearance of the skin is a major concern to most people.
Enhancing the appearance of the skin is of significant interest for many people. The appearance of the skin can be affected by many sources including environmental conditions such as sun exposure, building heating and air conditioning, and air pollution can accelerate deterioration of the condition and appearance of skin.
Additionally, certain diseases can affect the appearance of the skin. Deterioration of the appearance of the skin may include, but is not limited to, wrinkles, loss of firmness and elasticity of the skin, age spots, discolorations, and dryness. In addition, individual factors such as diet, stress, age and genetics may affect the appearance of the skin.
Various compositions and methods for manipulating the appearance of the skin have been reported. For example, international patent application, published under number WO/2004/100889, describes anti-ageing agents, including 3,3'-thiodipropionic acid or derivatives thereof for improving the aesthetic appearance of skin.
Another method of manipulating the quality of the skin is cosmetic surgery. It has been reported Date Recue/Date Received 2021-09-02 that seaweed extracts can be incorporated in compositions for use on the skin (see, for e.g., United States patent application 2004/0219124).
SUMMARY OF THE INVENTION
In accordance with one aspect of the invention there is provided a cosmetic composition for applying to skin. The composition includes a liquid, and dispersed in the liquid an amount of fucoidan, an amount of beta glucan, and an amount of a marine extract, wherein the cosmetic composition improves the appearance of the skin to which the composition is applied.
The composition may further include water as the liquid. The composition may further include the liquid being a glycolic acid-salicylic acid solution. The composition may further include the liquid being water and a glycolic acid-salicylic acid solution. The composition may further include the marine extract being any one or more of a green seaweed, a brown seaweed, an exopolysaccharide, or an algae. The composition may further include the marine extract being Ulva lactuta, Alteromonas maclodeii, Astaxanthin, or EckIonia cava.
In another aspect of the invention, the composition may include an amount of tourmaline. In another aspect of the invention, the composition may include an amount of volcanic obsidian. In another aspect of the invention, the composition may include an amount of Aloe barbadensis. In another aspect of the invention, the composition may include an amount of hydrolyzed pearl nacre. In another aspect of the invention, the composition may include an amount of chitosan. In another aspect of the invention, the composition may include an amount of a phospholipid.
In accordance with another aspect of the invention, the composition may include an amount of glyceryl stearate. In another aspect of the invention, the composition may include an amount of stearic acid. In another aspect of the invention, the composition may include an amount of cetearyl alcohol. In another aspect of the invention, the composition may include an amount of ceteareth 20. In another aspect of the invention, the composition may include an amount of isopropyl palmitate. In another aspect of the invention, the composition may include an amount of ascorbyl polypeptide. In another aspect of the invention, the composition may include an amount of tocotrienol.
In another aspect of the invention, the composition may include an amount of tocopheryl acetate. In Date Recue/Date Received 2021-09-02
-3-another aspect of the invention, the composition may include an amount of ergocalciferol.
In another aspect of the invention, the composition may include an amount of niacinamide.
In another aspect of the invention, the composition may include an amount of ferulic acid.
In another aspect of the invention, the composition may include an amount of Camellia sinensis. In another aspect of the invention, the composition may include an amount of Centella asiatica. In another aspect of the invention, the composition may include an amount of Chamomile matricaria. In another aspect of the invention, the composition may include an amount of Echinacea augustifolia.
In accordance with another aspect of the invention, the composition may include an amount of Ginko biloba. In another aspect of the invention, the composition may include an amount of butylene glycol. In another aspect of the invention, the composition may include an amount of phenoxyethanol. In another aspect of the invention, the composition may include an amount of caprylyl glycol. In another aspect of the invention, the composition may include an amount of sorbic acid. In another aspect of the invention, the composition may include an amount of peg8/SMDI copolymer. In another aspect of the invention, the composition may include an amount of superoxide dismutase liposomes.
In another aspect of the invention, the composition may include an amount of N-acetyl carnitine. In another aspect of the invention, the composition may include an amount of alpha lipoic acid. In another aspect of the invention, the composition may include an amount ofl-arginine.
In accordance with another aspect of the invention, the composition may include an amount of Glycine sofa. In another aspect of the invention, the composition may include an amount of Rumex crispis. In another aspect of the invention, the composition may include an amount of Vitis vinifera. In another aspect of the invention, the composition may include an amount of hinokitiol. In another aspect of the invention, the composition may include an amount of retinol. In another aspect of the invention, the composition may include an amount of Panax ginseng. In another aspect of the invention, the composition may include an amount of allantoin. In another aspect of the invention, the composition may include an amount of kaolin. In another aspect of the invention, the composition may include an amount of bentonite. hi another aspect of the invention, the composition may include an amount of Undaria pinnatifida. In another aspect of the invention, the composition may include an amount of diatomite silica. In another aspect Date Recue/Date Received 2021-09-02
In another aspect of the invention, the composition may include an amount of niacinamide.
In another aspect of the invention, the composition may include an amount of ferulic acid.
In another aspect of the invention, the composition may include an amount of Camellia sinensis. In another aspect of the invention, the composition may include an amount of Centella asiatica. In another aspect of the invention, the composition may include an amount of Chamomile matricaria. In another aspect of the invention, the composition may include an amount of Echinacea augustifolia.
In accordance with another aspect of the invention, the composition may include an amount of Ginko biloba. In another aspect of the invention, the composition may include an amount of butylene glycol. In another aspect of the invention, the composition may include an amount of phenoxyethanol. In another aspect of the invention, the composition may include an amount of caprylyl glycol. In another aspect of the invention, the composition may include an amount of sorbic acid. In another aspect of the invention, the composition may include an amount of peg8/SMDI copolymer. In another aspect of the invention, the composition may include an amount of superoxide dismutase liposomes.
In another aspect of the invention, the composition may include an amount of N-acetyl carnitine. In another aspect of the invention, the composition may include an amount of alpha lipoic acid. In another aspect of the invention, the composition may include an amount ofl-arginine.
In accordance with another aspect of the invention, the composition may include an amount of Glycine sofa. In another aspect of the invention, the composition may include an amount of Rumex crispis. In another aspect of the invention, the composition may include an amount of Vitis vinifera. In another aspect of the invention, the composition may include an amount of hinokitiol. In another aspect of the invention, the composition may include an amount of retinol. In another aspect of the invention, the composition may include an amount of Panax ginseng. In another aspect of the invention, the composition may include an amount of allantoin. In another aspect of the invention, the composition may include an amount of kaolin. In another aspect of the invention, the composition may include an amount of bentonite. hi another aspect of the invention, the composition may include an amount of Undaria pinnatifida. In another aspect of the invention, the composition may include an amount of diatomite silica. In another aspect Date Recue/Date Received 2021-09-02
-4-of the invention, the composition may include an amount of n-acetyl glucosamine. In another aspect of the invention, the composition may include an amount of phytoplankton.
In another aspect of the invention, the composition may include an amount of a member of the Skeletonema. In another aspect of the invention, the composition may include an amount of a member of the Thalassiosira. In another aspect of the invention, the composition may include an amount of a member of the Chaetoceros. In another aspect of the invention, the composition may include an amount of Fucus vesiculosus. In another aspect of the invention, the composition may include an amount of sodium pCA.
In another aspect of the invention, the composition may include an amount of magnesium ascorbyl phosphate. In another aspect of the invention, the composition may include an amount of epigallocatechin (EGCG). In another aspect of the invention, the composition may include an amount of ellagic acid. In another aspect of the invention, the composition may include an amount of sodium citrate. In another aspect of the invention, the composition may include an amount of tetrasodium EDTA. In another aspect of the invention, the composition may include an amount of an emollient. In another aspect of the invention, the composition may include an amount of a sunscreen. The sunscreen may be an organic sunscreen. The sunscreen may be an inorganic sunscreen. In another aspect of the invention, the composition may include an amount of a silicone surfactant. The silicone surfactant may be cyclomethicone or dimethicone copolyol.
In another aspect of the invention, the composition may include an amount of a preservative. The preservative may be methylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropyl biguamide. In another aspect of the invention, the composition may include an amount of an aqueous botanical antioxidant. The aqueous botanical antioxidant may be hydroxytyrosol, rutin, silymarin, turmeric, genistein, apple, green coffee, quercetin, or rosemary. In another aspect of the invention, the composition may include an amount of a humectant. The humectant may be a glycerol, a sorbitol, or a polyol. In another aspect of the invention, the composition may include an amount of a thickener. The thickener may be a cosmetic gum. The cosmetic gum may be alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester, modified potato starch, or pectin.
In another aspect of the invention, the composition may include an amount of an oligomer.
The oligomer may be iso-olefin, isodecane, hydrogenated polybutene, hydrogenated Date Recue/Date Received 2021-09-02
In another aspect of the invention, the composition may include an amount of a member of the Skeletonema. In another aspect of the invention, the composition may include an amount of a member of the Thalassiosira. In another aspect of the invention, the composition may include an amount of a member of the Chaetoceros. In another aspect of the invention, the composition may include an amount of Fucus vesiculosus. In another aspect of the invention, the composition may include an amount of sodium pCA.
In another aspect of the invention, the composition may include an amount of magnesium ascorbyl phosphate. In another aspect of the invention, the composition may include an amount of epigallocatechin (EGCG). In another aspect of the invention, the composition may include an amount of ellagic acid. In another aspect of the invention, the composition may include an amount of sodium citrate. In another aspect of the invention, the composition may include an amount of tetrasodium EDTA. In another aspect of the invention, the composition may include an amount of an emollient. In another aspect of the invention, the composition may include an amount of a sunscreen. The sunscreen may be an organic sunscreen. The sunscreen may be an inorganic sunscreen. In another aspect of the invention, the composition may include an amount of a silicone surfactant. The silicone surfactant may be cyclomethicone or dimethicone copolyol.
In another aspect of the invention, the composition may include an amount of a preservative. The preservative may be methylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropyl biguamide. In another aspect of the invention, the composition may include an amount of an aqueous botanical antioxidant. The aqueous botanical antioxidant may be hydroxytyrosol, rutin, silymarin, turmeric, genistein, apple, green coffee, quercetin, or rosemary. In another aspect of the invention, the composition may include an amount of a humectant. The humectant may be a glycerol, a sorbitol, or a polyol. In another aspect of the invention, the composition may include an amount of a thickener. The thickener may be a cosmetic gum. The cosmetic gum may be alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester, modified potato starch, or pectin.
In another aspect of the invention, the composition may include an amount of an oligomer.
The oligomer may be iso-olefin, isodecane, hydrogenated polybutene, hydrogenated Date Recue/Date Received 2021-09-02
-5-polydecene, polycaprolactone, fibronectin or polyethylene glycol. In another aspect of the invention, the composition may include an amount or combination of an amino acid. The amino acid may be present in its natural form. The amino acid may be a synethetic amino acid.
In another aspect of the invention, the composition may include an amount of a mineral and its salt. The mineral may be calcium, magnesium, manganese, or zinc. In another aspect of the invention, the composition may include an amount of a base. The base may be a soluble plant butter, a soluble plant wax, an anhydrous plant based cholesterol base, a phycocolloid gel base, a prepared polyethylene glycol ointment base, or a prepared carbomer gel base. In another aspect of the invention, the composition may include an amount of a marine component. The marine component may be an Enteromorpha species, a Porphyra species, a Chrondus species, a Laminares species, a kelp species or a Fucals species. In another aspect of the invention, the composition may include an amount of an anti-inflammatory agent. The anti-inflammatory agent may be Glycyrrhiza glabria, Boswellia serrate, Curcuma longa, turmeric, Arnica montana, silymarin, water melon, calendula, eidelweiss, or ginger. In another aspect of the invention, the composition may include an amount of a surfactant. The surfactant may be amphoteric. The surfactant may be cocomidopropyl betaine. The surfactant may be non-ionic. The surfactant may be cocoglucoside or coco polyglucose. The surfactant may be cationic. The surfactant may be lauryl dimoniumhydrolysed collagen.
In another aspect of the invention, the composition may include an amount of a percutaneous penetration enhancer. The percutaneous penetration enhancer may be polyethylene glycol or oleic acid. In another aspect of the invention, the composition may include an amount of a preservative enhancer. The preservative enhancer may be ethylhexyl glycerin, benzethonym chloride, or a hydantoin/PCB blend. In another aspect of the invention, the composition may include an amount of a vasodilator. The vasodilator may be adenosine triphosphate or liposomal 1 arginine. In another aspect of the invention, the composition may include an amount of a vasoconstrictor. The vasoconstrictor may be sea buckthorn, milk thistle, or marshmallow root. In another aspect of the invention, the composition may include an amount of a whitening agent. In another aspect of the invention, the composition may include an amount of a tyrosinase inhibitor.
The tyrosinase inhibitor may be selected from the Glycyrrhiza species. The tyrosinase Date Recue/Date Received 2021-09-02
In another aspect of the invention, the composition may include an amount of a mineral and its salt. The mineral may be calcium, magnesium, manganese, or zinc. In another aspect of the invention, the composition may include an amount of a base. The base may be a soluble plant butter, a soluble plant wax, an anhydrous plant based cholesterol base, a phycocolloid gel base, a prepared polyethylene glycol ointment base, or a prepared carbomer gel base. In another aspect of the invention, the composition may include an amount of a marine component. The marine component may be an Enteromorpha species, a Porphyra species, a Chrondus species, a Laminares species, a kelp species or a Fucals species. In another aspect of the invention, the composition may include an amount of an anti-inflammatory agent. The anti-inflammatory agent may be Glycyrrhiza glabria, Boswellia serrate, Curcuma longa, turmeric, Arnica montana, silymarin, water melon, calendula, eidelweiss, or ginger. In another aspect of the invention, the composition may include an amount of a surfactant. The surfactant may be amphoteric. The surfactant may be cocomidopropyl betaine. The surfactant may be non-ionic. The surfactant may be cocoglucoside or coco polyglucose. The surfactant may be cationic. The surfactant may be lauryl dimoniumhydrolysed collagen.
In another aspect of the invention, the composition may include an amount of a percutaneous penetration enhancer. The percutaneous penetration enhancer may be polyethylene glycol or oleic acid. In another aspect of the invention, the composition may include an amount of a preservative enhancer. The preservative enhancer may be ethylhexyl glycerin, benzethonym chloride, or a hydantoin/PCB blend. In another aspect of the invention, the composition may include an amount of a vasodilator. The vasodilator may be adenosine triphosphate or liposomal 1 arginine. In another aspect of the invention, the composition may include an amount of a vasoconstrictor. The vasoconstrictor may be sea buckthorn, milk thistle, or marshmallow root. In another aspect of the invention, the composition may include an amount of a whitening agent. In another aspect of the invention, the composition may include an amount of a tyrosinase inhibitor.
The tyrosinase inhibitor may be selected from the Glycyrrhiza species. The tyrosinase Date Recue/Date Received 2021-09-02
-6-inhibitor may be a favnoid, a polyphenol, an isoflavon, or a coumarin. In another aspect of the invention, the composition may include an amount of octadecnedioic acid. In another aspect of the invention, the composition may include an amount of chalcones.
In another aspect of the invention the composition may be absorbed by human skin. In another aspect of the invention the composition may be homogeneous.
Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
DETAILED DESCRIPTION
Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the art of the invention.
Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of embodiments of the invention, and how to make or use them. It will be appreciated that the same thing may be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein.
Some synonyms or substitutable methods, materials and the like are provided.
Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples in the specification, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the embodiments of the invention herein.
In accordance with one aspect of the invention there is provided a cosmetic composition for applying to skin. The composition is comprised of a liquid and dispersed in the liquid is an amount or form of fucoidan, an amount or form of beta glucan, and an amount of a marine extract. When applied to the skin, the cosmetic composition improves the appearance of the skin. Improved appearance of the skin may be associated with any one of the following but is not limited to the following: decreased skin wrinkles, increased skin smoothness, decreased roughness of the skin, increased luminosity of the skin, increased clarity of the skin, increased firmness of the skin, increased tautness of the skin, decreased irritation of the skin, decreased skin-associated inflammation, improved skin Date Recue/Date Received 2021-09-02
In another aspect of the invention the composition may be absorbed by human skin. In another aspect of the invention the composition may be homogeneous.
Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
DETAILED DESCRIPTION
Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the art of the invention.
Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of embodiments of the invention, and how to make or use them. It will be appreciated that the same thing may be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein.
Some synonyms or substitutable methods, materials and the like are provided.
Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples in the specification, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the embodiments of the invention herein.
In accordance with one aspect of the invention there is provided a cosmetic composition for applying to skin. The composition is comprised of a liquid and dispersed in the liquid is an amount or form of fucoidan, an amount or form of beta glucan, and an amount of a marine extract. When applied to the skin, the cosmetic composition improves the appearance of the skin. Improved appearance of the skin may be associated with any one of the following but is not limited to the following: decreased skin wrinkles, increased skin smoothness, decreased roughness of the skin, increased luminosity of the skin, increased clarity of the skin, increased firmness of the skin, increased tautness of the skin, decreased irritation of the skin, decreased skin-associated inflammation, improved skin Date Recue/Date Received 2021-09-02
-7-tone, improved hydration of the skin, decreased dryness of the skin, improvements in skin discoloration, and decreased breakouts of skin conditions such as acne.
Optionally, the liquid may be water, and can include but is not limited to distilled water. Optionally, the liquid may be a glycolic acid-salicylic acid solution.
Further, and optionally, the liquid may be a combination of water, including but not limited to distilled water, and a glycolic acid-salicylic acid solution. Optionally, the marine extract used in the combination may include one or more of a green seaweed, a brown seaweed, an exopolysaccharide, or an algae. A green seaweed may include but is not limited to the Ulva genus and particularly Ulva lactuta. A brown seaweed may include but is not limited to laminariales, which is commonly known as kelp, and fucals. A brown seaweed may include Ecklonia cava. An expolysaccharide is understood to be a high-molecular-weight polymer of sugar residues. Algae may include but are not limited to members of the following groups: Archaeplastida, Rhizaria, Excavata, Excavata, Chromista, and Alveolata. Optionally, the composition may include a marine extract selected from any one or more of the following: Ulva lactuta, Alteromonas maclodeii, Astaxanthin, or Ecklonia cava.
Optionally, the composition may include an amount of tourmaline. Optionally, the composition may include an amount of volcanic obsidian. The composition may include an amount of Aloe barbadensis. The composition may further include an amount of hydrolyzed pearl nacre. Optionally, the composition may include an amount of chitosan.
Optionally, the composition may include an amount of a phospholipid. A
phospholipid is understood as being any of a variety of phosphorous-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule.
Optionally, the composition may include an amount of glyceryl stearate. Optionally, the composition may include an amount of stearic acid. Optionally, the composition may include an amount of cetearyl alcohol.
Further, the composition may include an amount of ceteareth 20. The composition may also include an amount of isopropyl palmitate. Optionally, the composition may include an amount of one or more of the following: ascorbyl polypeptide, tocotrienol, tocopheryl acetate, ergocalciferol, niacinamide, or ferulic acid.
Optionally, the composition may include an amount of Camellia sinensis. Further, the composition may include an amount of one or more of the following: Centella asiatica, Chamomile Date Recue/Date Received 2021-09-02
Optionally, the liquid may be water, and can include but is not limited to distilled water. Optionally, the liquid may be a glycolic acid-salicylic acid solution.
Further, and optionally, the liquid may be a combination of water, including but not limited to distilled water, and a glycolic acid-salicylic acid solution. Optionally, the marine extract used in the combination may include one or more of a green seaweed, a brown seaweed, an exopolysaccharide, or an algae. A green seaweed may include but is not limited to the Ulva genus and particularly Ulva lactuta. A brown seaweed may include but is not limited to laminariales, which is commonly known as kelp, and fucals. A brown seaweed may include Ecklonia cava. An expolysaccharide is understood to be a high-molecular-weight polymer of sugar residues. Algae may include but are not limited to members of the following groups: Archaeplastida, Rhizaria, Excavata, Excavata, Chromista, and Alveolata. Optionally, the composition may include a marine extract selected from any one or more of the following: Ulva lactuta, Alteromonas maclodeii, Astaxanthin, or Ecklonia cava.
Optionally, the composition may include an amount of tourmaline. Optionally, the composition may include an amount of volcanic obsidian. The composition may include an amount of Aloe barbadensis. The composition may further include an amount of hydrolyzed pearl nacre. Optionally, the composition may include an amount of chitosan.
Optionally, the composition may include an amount of a phospholipid. A
phospholipid is understood as being any of a variety of phosphorous-containing lipids that are composed mainly of fatty acids, a phosphate group, and a simple organic molecule.
Optionally, the composition may include an amount of glyceryl stearate. Optionally, the composition may include an amount of stearic acid. Optionally, the composition may include an amount of cetearyl alcohol.
Further, the composition may include an amount of ceteareth 20. The composition may also include an amount of isopropyl palmitate. Optionally, the composition may include an amount of one or more of the following: ascorbyl polypeptide, tocotrienol, tocopheryl acetate, ergocalciferol, niacinamide, or ferulic acid.
Optionally, the composition may include an amount of Camellia sinensis. Further, the composition may include an amount of one or more of the following: Centella asiatica, Chamomile Date Recue/Date Received 2021-09-02
-8-matricaria, Echinacea augustifolia, or Ginko biloba. Optionally, the composition may include an amount of one or more of the following: butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, peg8/SMDI copolymer, superoxide dismutase liposomes, N-acetyl carnitine, alpha lipoic acid, or 1-arginine.
Further, the composition may include an amount of one or more of the following:
Glycine sofa, Rumex crispis, Vitis vinffera, hinokitiol, retinol, Panax ginseng, allantoin, kaolin, bentonite, Undaria pinnatifida, diatomite silica, or n-acetyl gjucosamine. The composition may further include an amount of a phytoplankton species. The composition may include an amount of a member of the Skeletonema. The composition may include an amount of a member of the Thalassiosira. The composition may include an amount of a member of the Chaetoceros.
Further, the composition may include an amount of Fucus vesiculosus. The composition may include an amount of one or more of the following: sodium pCA, magnesium ascorbyl phosphate, epigallocatechin (EGCG), ellagic acid, sodium citrate, or tetrasodium EDTA. The composition may include an amount of an emollient. An emollient is understood as being a material used for the prevention or relief of dryness, as well as for the protection of the skin.
The composition may include an amount of a sunscreen. The sunscreen may be an organic sunscreen. According to an embodiment of the invention, the composition may include from approximately 0.1 to approximately 10%, and preferably from approximately 1 to approximately 5% by weight of an organic sunscreen material. The sunscreen may be an inorganic sunscreen. According to an embodiment of the invention, the composition may include an inorganic sunscreen such as titanium dioxide or zinc oxide, having an average particle size of from 1 to 300 rim, or iron oxide, having an average particle size of from 1 to 300 nrn, or silica, having an average particle size of from 1 to 100 nm.
The composition may include an amount of a silicone surfactant, which may include but is not limited to cyclomethicone or dimethicone copolyol. The composition may include an amount of a preservative. Examples of a preservative include but are not limited to methylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropyl biguamide.
Further, the composition may include an amount of an aqueous botanical antioxidant. Examples of an aqueous botanical antioxidant include, but are not limited to:
Date Recue/Date Received 2021-09-02
Further, the composition may include an amount of one or more of the following:
Glycine sofa, Rumex crispis, Vitis vinffera, hinokitiol, retinol, Panax ginseng, allantoin, kaolin, bentonite, Undaria pinnatifida, diatomite silica, or n-acetyl gjucosamine. The composition may further include an amount of a phytoplankton species. The composition may include an amount of a member of the Skeletonema. The composition may include an amount of a member of the Thalassiosira. The composition may include an amount of a member of the Chaetoceros.
Further, the composition may include an amount of Fucus vesiculosus. The composition may include an amount of one or more of the following: sodium pCA, magnesium ascorbyl phosphate, epigallocatechin (EGCG), ellagic acid, sodium citrate, or tetrasodium EDTA. The composition may include an amount of an emollient. An emollient is understood as being a material used for the prevention or relief of dryness, as well as for the protection of the skin.
The composition may include an amount of a sunscreen. The sunscreen may be an organic sunscreen. According to an embodiment of the invention, the composition may include from approximately 0.1 to approximately 10%, and preferably from approximately 1 to approximately 5% by weight of an organic sunscreen material. The sunscreen may be an inorganic sunscreen. According to an embodiment of the invention, the composition may include an inorganic sunscreen such as titanium dioxide or zinc oxide, having an average particle size of from 1 to 300 rim, or iron oxide, having an average particle size of from 1 to 300 nrn, or silica, having an average particle size of from 1 to 100 nm.
The composition may include an amount of a silicone surfactant, which may include but is not limited to cyclomethicone or dimethicone copolyol. The composition may include an amount of a preservative. Examples of a preservative include but are not limited to methylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropyl biguamide.
Further, the composition may include an amount of an aqueous botanical antioxidant. Examples of an aqueous botanical antioxidant include, but are not limited to:
Date Recue/Date Received 2021-09-02
-9-hydroxytyrosol, rutin, silymarin, turmeric, genistein, apple, green coffee, quercetin, or rosemary. Further, the composition may include an amount of a humectant. The humectant may be a glycerol, a sorbitol, or a polyol. The humectant chosen is not limited to the foregoing list of humectants.
The composition may include an amount of a thickener, including but not limited to, a cosmetic gum. The cosmetic gum may include, but is not limited to, alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester, modified potato starch, or pectin.
Further, the composition may include an amount of an oligomer, including but not limited to, an oligomer of iso-olefin, isodecane, hydrogenated polybutene, hydrogenated polydecene, polycaprolactone, fibronectin or polyethylene glycol. An oligomer is understood as representing a few of the aforementioned monomeric units.
The composition may include an amount of an amino acid. The composition may include a combination of amino acids, for example, a peptide comprised of amino acids.
The amino acid may be in its natural form or it may be a synthetic amino acid.
An amino acid may be described as, for example, polar, non-polar, acidic, basic, aromatic or neutral.
A polar amino acid is an amino acid that may interact with water by hydrogen bonding at biological or near-neutral pH. The polarity of an amino acid is an indicator of the degree of hydrogen bonding at biological or near-neutral pH. Examples of polar amino acids include serine, proline, threonine, cysteine, asparagine, glutamine, lysine, histidine, arginine, aspartate, tyrosine and glutamate. Examples of non-polar amino acids include glycine, alanine, valine leucine, isoleucine, methionine, phenylalanine, and tryptophan.
Acidic amino acids have a net negative charge at a neutral pH. Examples of acidic amino acids include aspartate and glutamate. Basic amino acids have a net positive charge at a neutral pH. Examples of basic amino acids include arginine, lysine and histidine.
Aromatic amino acids are generally nonpolar, and may participate in hydrophobic interactions. Examples of aromatic amino acids include phenylalanine, tyrosine and tryptophan. Tyrosine may also participate in hydrogen bonding through the hydroxyl group on the aromatic side chain. Neutral, aliphatic amino acids are generally nonpolar and hydrophobic. Examples of neutral amino acids include alanine, valine, leucine, isoleucine and methionine. An amino acid may be described by more than one descriptive Date Recue/Date Received 2021-09-02
The composition may include an amount of a thickener, including but not limited to, a cosmetic gum. The cosmetic gum may include, but is not limited to, alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester, modified potato starch, or pectin.
Further, the composition may include an amount of an oligomer, including but not limited to, an oligomer of iso-olefin, isodecane, hydrogenated polybutene, hydrogenated polydecene, polycaprolactone, fibronectin or polyethylene glycol. An oligomer is understood as representing a few of the aforementioned monomeric units.
The composition may include an amount of an amino acid. The composition may include a combination of amino acids, for example, a peptide comprised of amino acids.
The amino acid may be in its natural form or it may be a synthetic amino acid.
An amino acid may be described as, for example, polar, non-polar, acidic, basic, aromatic or neutral.
A polar amino acid is an amino acid that may interact with water by hydrogen bonding at biological or near-neutral pH. The polarity of an amino acid is an indicator of the degree of hydrogen bonding at biological or near-neutral pH. Examples of polar amino acids include serine, proline, threonine, cysteine, asparagine, glutamine, lysine, histidine, arginine, aspartate, tyrosine and glutamate. Examples of non-polar amino acids include glycine, alanine, valine leucine, isoleucine, methionine, phenylalanine, and tryptophan.
Acidic amino acids have a net negative charge at a neutral pH. Examples of acidic amino acids include aspartate and glutamate. Basic amino acids have a net positive charge at a neutral pH. Examples of basic amino acids include arginine, lysine and histidine.
Aromatic amino acids are generally nonpolar, and may participate in hydrophobic interactions. Examples of aromatic amino acids include phenylalanine, tyrosine and tryptophan. Tyrosine may also participate in hydrogen bonding through the hydroxyl group on the aromatic side chain. Neutral, aliphatic amino acids are generally nonpolar and hydrophobic. Examples of neutral amino acids include alanine, valine, leucine, isoleucine and methionine. An amino acid may be described by more than one descriptive Date Recue/Date Received 2021-09-02
-10-category. Amino acids sharing a common descriptive category may be substitutable for each other in a peptide.
An amino acid residue may be generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following Table A.
Amino acids comprising the peptides described herein will be understood to be in the L- or D- configuration.
Amino acids described herein, may be modified by methylation, amidation, acetylation or substitution with other chemical groups which may change the circulating half-life of the peptide without adversely affecting their biological activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention.
Nonstandard amino acids may occur in nature, and may or may not be genetically encoded.
Examples of genetically encoded nonstandard amino acids include selenocysteine, sometimes incorporated into some proteins at a UGA codon, which may normally be a stop codon, or pyrrolysine, sometimes incorporated into some proteins at a UAG codon, which may normally be a stop codon. Some nonstandard amino acids that are not genetically encoded may result from modification of standard amino acids already incorporated in a peptide, or may be metabolic intermediates or precursors, for example.
Examples of nonstandard amino acids include 4-hydroxyproline, 5-hydroxylysine, methyllysine, gamma-carboxyglutamate, desmosine, selenocysteine, ornithine, citrulline, lanthionine, 1-aminocyclopropane-1 -carboxylic acid, gamma-aminobutyric acid, camitine, sarcosine, or N-formylmethionine. Synthetic variants of standard and non-standard amino acids are also known and may include chemically derivatized amino acids, amino acids labeled for identification or tracking, or amino acids with a variety of side groups on the alpha carbon. Examples of such side groups are known in the art and may include aliphatic, single aromatic, polycyclic aromatic, heterocyclic, heteronuclear, amino, alkylamino, carboxyl, carboxamide, carboxyl ester, guanidine, amidine, hydroxyl, alkoxy, mercapto-, alkyhnercapto-, or other heteroatom-containing side chains. Other synthetic amino acids may include alpha-amino acids, non-alpha Date Recue/Date Received 2021-09-02 Table A. Nomenclature and abbreviations of the 20 standard L-amino acids commonly found in naturally occurring peptides Full name Three-letter abbreviation .. One-letter abbreviation Alanine Ala A
Cysteine Cys Aspartic acid Asp Glutamic acid Glu Phenylalanine Phe Glycine Gly Histidine His Isoleucine Ile Lysine Lys Leucine Leu Methionine Met Asparagine Asp Proline Pro Glutamine Gin Arginine Arg Serine Ser Threonine Thr Valine Val V
Tryptophan Trp Tyrosine Tyr Date Recue/Date Received 2021-09-02 amino acids such as beta-amino acids, des-carboxy or des-amino acids.
Synthetic variants of amino acids may be synthesized using general methods known in the art, or may be purchased from commercial suppliers, for example RSP Amino Acids LLC (Shirley, MA).
Additionally, the composition may include an amount of a mineral and its salt.
The mineral may be calcium, magnesium, manganese, or zinc. The mineral chosen is not limited to the aforementioned minerals. The composition may include an amount of a base, including but not limited to, a soluble plant butter, a soluble plant wax, an anhydrous plant based cholesterol base, a phycocolloid gel base, a prepared polyethylene glycol ointment base, or a prepared carbomer gel base. The composition may include an amount of a marine component including, but not limited to, any one or more of the following: an Enteromorpha species, a Porphyra species, a Chrondus species, a Laminares species, a kelp species or a Fucals species. The marine component or seaweed utilized in the composition can be selected from the group consisting of brown algae, red algae and green algae. Further the marine component or seaweed utilized in the composition can be selected by pre-determining the content of any one of the following in the marine component: natural amino acids, fatty acids and their glycosyl derivatives, sterols, natural antimicrobials, ursolic acid, or mono / polysaccharides. Methods for analyzing the above are known in the art and include but are not limited to the techniques disclosed in Sanchez-Machado et al. (2004) BMC 18(3):183-90.
Further, the composition may include an amount of an anti-inflammatory agent.
The anti-inflammatory agent may include, but is not limited to, any one or more of the following: Glycyrrhiza glabria, Boswellia serrate, Curcuma longa, turmeric, Arnica montana, silymarin, water melon, calendula, eidelweiss, or ginger.
The composition may include an amount of a surfactant. The surfactant may be amphoteric. They surfactant may be, but is not limited to, cocomidopropyl betaine. The surfactant may be non-ionic. The surfactant may be, but is not limited to, cocoglucoside or coco polyglucose. The surfactant may be cationic. The surfactant may be, but is not limited to, lauryl dimoniumhydrolysed collagen.
The composition may include an amount of a percutaneous penetration enhancer including, but not limited to, any one or more of the following: polyethylene glycol or oleic acid. The composition may include an amount of a preservative enhancer including, but not limited to, any one or more of the following: ethylhexyl glycerin, benzethonym Date Recue/Date Received 2021-09-02 chloride, or a hydantoin/PCB blend. Further, the composition may include an amount of a vasodilator including, but not limited to, any one of the following: adenosine triphosphate or liposomal 1 arginine.
Further, the composition may include an amount of a vasoconstrictor including, but not limited to, any one or more of the following: sea buckthorn, milk thistle, or marshmallow root. Additionally, the composition may include an amount of a whitening agent. The composition may include an amount of a tyrosinase inhibitor including, but not limited to, an inhibitor selected from the Glycyrrhiza species. The tyrosinase inhibitor may include, but is not limited to, a favnoid, a polyphenol, an isoflavon, or a coumarin.
Further, the composition may include an amount of octadecnedioic acid or chalcones or a combination thereof.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of skill in the art in light of teachings of this invention that changes and modification may be made thereto without departing from the spirit or scope of the invention.
EXAMPLES
Example 1. Composition with acidified fucoidan, beta glucan, and ascorbyl polypeptide In accordance with an embodiment of the present invention, a composition is described having the components shown in Table 1 below. The methodology employed in producing the composition using the amounts described in Table 1 below is generally as follows.
Method Sequence No. 1 In a first mixture, neutralized glycolic and salicyclic acid solution (source:
Spectrum Chemical; Gardena, California) was heated in a stainless steel container to approximately 85 degrees Celsius. The seaweed complex consisting of Ulva lactuta, Alteromonas maclodeii, and astaxanthin (source: Unipex Innovations, Mississauga, Ontario) was added to the heated glycolic acid mixture. The combined mixture was mixed for approximately 45 to 60 minutes.
Date Recue/Date Received 2021-09-02 Table 1. Components of an embodiment of the Invention Sequence No. Component Amount (%
by weight) Glycolic acid-salicylic acid solution (ratio: 8:1) 10 (neutralized with ammonium hydroxide; ammonium glycolate, sodium lactate can also be added to obtain a preferable pH of -4) Seaweed complex containing Ulva lactuta, 5.5 Alteromonas maclodeii and Astaxanthin (ratio:
7:1.5:1.5) Distilled Water 20.8 Tourmaline (0.15%) and volcanic obsidian (0.05%) 0.2 Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio) and fucoidan complex (beta glucan and fucoidan are present in a 1:1 ratio) Aqueous Aloe barbadensis extract 10 Hydrolyzed pearl nacre (1.5%) and chitosan (0.5%) 2.5 Phospholipids 10 Glyceryl stearate, stearic acid, cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex (each of these products is added at an equal amount) Ascorbyl polypeptide, tocotrienol, tocopheryl 6 acetate, ergocalciferol, niacinamide complex (ratio of these products: 3:1:1:1:1:1) Aqueous extract of Camellia sinensis, Centella 1.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (each of these products is added at an equal amount) Complex of butylene glycol, phenoxyethanol, 2.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer (these products are added at the following ratio: 1.5:
0.5 : 0.25 : 0.25 : 0.25) Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 A polarized water was developed by adding tourmaline and obsidian (source:
Soliance; Paris, France) to the distilled water. The beta glucan (source:
Biothera; Eagen, Minnesota) and fucoidan (source: Marinova; Cambridge, Tasmania, Australia) complex was dissolved in one-third of the polarized water. The dissolved beta glucan-fucoidan complex was added to the glycolic acid mixture (previously described above) and the entire solution was maintained at approximately 85 degrees Celsius for approximately 30 minutes. While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K Industries; Northvale, New Jersey) was added and the entire mixture was allowed to cool for approximately 30 minutes. Thereafter, hydrolyzed pearl nacre (source:
Active Concepts; Lincolnton, North Carolina) and chitosan (source: Alfa Chem;
Kings Point, New York) were added to the cooled mixture. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, phospholipids (source:
Arch Personal Care; Norwalk, Connecticut) were added to the cooled mixture.
Method Sequence No. 2 In a further mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.; Chicago, Illinois) were heated to 75 degrees Celsius in a 200 kg stainless steel vat. The mixture was mixed by continuous stirring for approximately 60 minutes.
Separately, the remaining two-thirds of polarized water (as described above) was used to dissolve the ascorbyl polypeptide-tocotrienol complex (source: Arch Personal Care). The ascorbyl polypeptide-tocotrienol complex was allowed to dissolve in the polarized water for approximately one hour. Thereafter, aqueous extracts of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko biloba (source: Active Organics; Louisville, Texas) were added to the ascorbyl polypeptide ¨ tocotrienol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer were added at the ratio described above to make a complex (source: International Specialty Products; Mississauga, Ontario). Thereafter, this complex was added to the glyceryl stearate complex mixture described above, the glyceryl stearate Date Recue/Date Received 2021-09-02 complex having been maintained at approximately 75 degrees Celsius.
Thereafter, the ascorbyl polypeptide-tocotrienol complex, which had previously been mixed with the aqueous extracts described above, was added and agitation of the mixture continued at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius.
Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 1 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 1.5% of the formulation instead of 5.5% as described in Table 1. Further, the beta glucan and fucoidan complex can be present as 12% of the formulation instead of 8% as described in Table 1.
Testing efficacy of Example 1 To test the efficacy of the mixture described in Example 1, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that following application of the mixture described in Example 1, the human subjects exhibited improved appearance of their skin.
Serving as an example, JT, a female under the age of 30 years of age, used the formulation defined in Example 1. Prior to using the formulation of Example 1, JT had exhibited sensitive skin and a tendency to have acne breakouts. JT also described numerous fine lines being visible in her forehead region. On day 0, JT began using an amount approximately equivalent to the size of a quarter and used approximately that amount each morning on her skin. After one week, JT described her skin as being brighter and with an improved complexion. After two weeks, JT described that the fine lines on her skin were blurred. After one month, JT described that her skin had less breakouts and was very smooth. JT identified at least the following attributes as being associated with the formulation defined in Example 1: increased smoothness and brightness of the skin, decreased lines on JT's forehead, and decreased breakouts of acne. Further, JT
identified the formulation of Example 1 as being associated with decreased dryness of the skin.
It was determined that the formulation/mixture of Example 1 was absorbed by human skin.
Date Recue/Date Received 2021-09-02 Example 2. Composition with non-acidified fucoidan and beta glucan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 2. The methodology employed in producing the composition using the amounts described in Table 2 is generally as follows.
Method Sequence No. I
In a first mixture, a polarized water was developed by adding tourmaline and obsidian (source: Soliance) to the distilled water. The seaweed complex consisting of Ulva lactuta, Astaxanthin, Alteromonas maclodeii (source: Unipex Innovations;
Quebec City, Quebec) was dissolved into one half of the polarized water. The mixture was maintained at approximately 85 degrees Celsius. While maintaining the temperature, the mixture was stirred for approximately 45 minutes to 60 minutes. Thereafter, beta glucan (source: Biothera) and fucoidan (source: Marinova) complex were dissolved in the seaweed complex-distilled water mixture. This mixture was maintained at approximately 85 degrees Celsius and the mixture was stirred for at least approximately 30 minutes.
Thereafter, while maintaining the mixing of the mixture, the aqueous Aloe barbedensis leaf extract (source: Tri K Industries) was added and the entire mixture was allowed to cool for approximately 30 minutes.
Therafter, hydrolyzed pearl nacre (source: Rita Corp.; Crystal Lake, Illinois) and chitosan (source: Alfa Chem), acetyl glucosomine (source: Alfa Chem), n-acetyl camatine (source: Alfa Chem), alpha lipoic acid (source: Alfa Chem), and 1-arginine (source: Alfa Chem) were added to the cooled mixture. The cooled mixture was further cooled to approximately 30 degrees Celsius. Thereafter, phospholipids (source: Arch Personal Care) and sodium hyaluronate (source: Tri-K Industries) were added to the mixture.
Date Recue/Date Received 2021-09-02 Table 2. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Distilled water 18.8 Tourmaline (0.15%) and volcanic obsidian (0.05%) 0.2 Seaweed complex containing Ulva lactuta, 10 Astaxanthin, Alteromonas maclodeii (ratio of these products: 7:1.5:1.5) Beta glucan (yeast and specified medicinal fungi 10 extract combined in a 1:1 ratio) and fucoidan complex (beta glucan and fucoidan are present in a 1:1 ratio) Aqueous Aloe barbedensis leaf extract 12 Hydrolyzed pearl nacre and chitosan (ratio of these 1.5 products: 1.5:1) N-acetyl carnitine, alpha lipoic acid, and I-arginine 3.5 (ratio of these products: 1.5:1.5:0.5) Phospholipids and sodium hyaluronate (ratio of these 8 products: 4:1) II Glyceryl stearate, stearic acid, cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex (each of these products is added at an equal amount) II Ascorbyl polypeptide, tocotrienol, tocopheryl acetate, 5 ergocalciferol, ferulic acid, niacinamide complex (ratio of these products: 3:1:0.5:0.5:0.5:0.5) II Glycine sofa, Rumex crispis, Vitis vinifera, hinokitiol 2 (beta thujaplicin) (each of these products is added at an equal amount) II Aqueous extract of Camellia sinensis, Centella 2.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (each of these products is added at an equal amount) Ill Complex of butylene glycol, phenoxyethanol, caprylyl 3.5 glycol, sorbic acid, peg8/SMDI copolymer (ratio of these products: 1.5:.05:0.25:0.25:0.25) III Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 Method Sequence No. 2 In a second mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, isopropyl palmitate complex (all from source: Hallstar Corp.) were heated to 75 degrees Celsius in a 200 kg. stainless steel vat. The mixture was mixed by continuous stirring for approximately 60 minutes.
Separately, ascorbyl polypeptide, tocotrienol, tocopheryl acetate, ergocalciferol, ferulic acid, and niacinamide (all from source: Arch Personal Care) were dissolved into the second half of the polarized water (as described above) over a period of approximately one hour. Thereafter, Glycine sofa, Rumex crispis, Vitis vinifera, and hinokitiol (beta thujaplicin) (all from source: Active Organics); and aqueous extracts of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko biloba (all from source: Active Organics) were added to the ascorbyl polypeptide-tocotrienol mixture.
Method Sequence No. 3 Butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid and peg8/SMDI
copolymer (all from source: International Specialty Products) were combined to form a complex.
Thereafter, the complex was added to the glyceryl stearate mixture described above, while the glyceryl stearate mixture was maintained at approximately 75 degrees Celsius.
Thereafter, the ascorbyl polypeptide-tocotrienol mixture described above was added and agitation of the mixture continued at approximately 75 degrees Celsius. The entire mixture was then cooled to approximately 30 degrees Celsius. Thereafter, the mixture developed above in Method Sequence No. 1 was added. Thereafter, the mixture was allowed to cool to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 2 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 4% of the formulation instead of 10% as described in Table 2. Further, the beta glucan and fucoidan complex can be present as 16% of the formulation instead of 10% as described in Table 2.
Date Recue/Date Received 2021-09-02 Testing efficacy of Example 2 To test the efficacy of the mixture described in Example 2, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 2 improved the appearance of the skin of human subjects.
Serving as an example, MJ, a female over the age of 40 years of age, used the formulation defined in Example 2. Prior to using the formulation of Example 2, MJ had exhibited under-eye skin that was puffy, sensitive and quite dry. On day 0, MJ
began using an amount approximately equivalent to the size of a dime and used approximately that amount each morning and night on her skin. After one week, MJ described her under-eye skin as being less puffy. After two weeks, MJ again described her under-eye skin as being less puffy. After one month, MJ described her under-eye skin as bein tighter looking and having fewer small wrinldes such that the skin appeared to be smoother in appearance. MJ identified at least the following attributes as being associated with the formulation defined in Example 2: decreased skin wrinldes; improvement in skin tone;
increased skin firmness; and increased skin hydration.
It was determined that the formulation/mixture of Example 2 was absorbed by human skin.
Example 3. Composition with acidified fucoidan, beta glucan and retinol In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 3. The methodology employed in producing the composition using the amounts described in Table 3 is generally as follows.
Method Sequence No.
In a first mixture, neutralized glycolic and salicylic acid solution (source:
Dupont or Spectrum Chemical) was heated in a stainless steel container to approximately 85 degrees Celsius. The seaweed complex consisting of Date Recue/Date Received 2021-09-02 Table 3. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Glycolic and salicylic acids (ratio: 8:1) (neutralized 10 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Seaweed complex containing EckIonia cava, 5.5 Alteromonas maclodeii and Astaxanthin [ratio:
7:1.5:1.5]
Distilled water 14.8 Tourmaline (0.15%) and volcanic obsidian (0.5%) 0.2 Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio) in a 1:1 ratio with fucoidan complex Aqueous Aloe barbedensis leaf extract 10 Hydrolyzed pearl nacre (1.5%) and chitosan (1.0%) 2.5 Phospholipids 10 Glyceryl stearate, stearic acid, cetearyl alcohol, 20 ceteareth 20, isopropyl palmitate (each of these products is added at an equal amount) Tocotrienol, tocopheryl acetate, niacinamide, retinol 6 complex (ratio of these products: 3:1.5:1.5:0.5) Aqueous extract of Vitis vinifera, Chamomile 2.5 matricaria, Echinacea augustifolia, Panax ginseng, Glycine sofa, allantoin (each of these products is added at an equal amount) Complex of butylene glycol, phenoxyethanol, 2.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer (ratio of these products: 1.5:0.5:0.25:0.25:0.25) Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 EckIonia cava, Alteromonas maclodeii, and Astaxanthin (source: Unipex Innovations) was added to the heated glycolic acid mixture. The combined mixture was mixed for approximately 45 to 60 minutes.
Polarized water was developed by adding tourmaline and obsidian (source:
Soliance) to the distilled water. The beta glucan and fucoidan complex (source: Active Concepts, Marinova) was dissolved in one-third of the polarized water. The dissolved beta glucan - fucoidan complex was added to the glycolic acid mixture (previously described above) and the entire solution continued to be stirred while the temperature was maintained at approximately 85 degrees Celsius for approximately 30 minutes.
While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K
Industries) was added and the entire mixture was allowed to cool for 30 minutes.
Thereafter, hydrolyzed pearl nacre (source: Rita Corp.) and chitosan (source:
Alfa Chem) were added to the cooled mixture. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, phospholipids (source: Arch Personal Care) were added to the cooled mixture.
Method Sequence No. 2 In a further mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.) were heated to 75 degrees Celsius in a 200 kg. stainless steel vat. The mixture was mixed by continuous stirring for 60 minutes.
Separately, the remaining two-thirds of polarized water (as described above) was used to dissolve the tocotrienol ¨ retinol complex (source: Arch Personal Care). The tocotrienol ¨ retinol complex was allowed to dissolve in the polarized water for one hour.
Thereafter, aqueous extracts of Vitis vinifera, Chamomile matricaria, Echinacea augustifolia, Panax ginseng, Glycine sofa, and allantoin (source: Active Organics) were added to the tocotrienol ¨ retinol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer were combined to make a complex (source: International Specialty Products). Thereafter, this complex was added to the glyceryl stearate complex Date Recue/Date Received 2021-09-02 mixture described above, the glyceryl stearate complex having been maintained at 75 degrees Celsius. Thereafter, the ascorbyl polypeptide-tocotrienol complex, which had previously been mixed with the aqueous extracts described above, was added and agitation of the mixture continued at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius.
Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 3 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 3.5% of the formulation instead of 5.5% as described in Table 3. Further, the beta glucan and fucoidan complex can be present as 10% of the formulation instead of 8% as described in Table 3.
Testing efficacy of Example 3 To test the efficacy of the mixture described in Example 3, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 3 improved the appearance of the skin of human subjects.
Serving as an example, CO, a female between the age of 30-40 years of age, used the formulation defined in Example 3. Prior to using the formulation of Example 3, CO
had exhibited oily skin that was prone to acne breakouts. Further, CO
described that her skin was rough, and that skin pores were visible. Further, CO described that her skin showed an appearance of acne scarring. On day 0, CO began using an amount approximately equivalent to the size of a dime and used approximately that amount each night on her skin. After one week, CO described her skin as having faded acne scarring.
After two weeks, CO described that her skin appeared to be more radiant and glowing in appearance. After one month, CO described her skin as being firmer and that the acne breakouts had stopped. CO identified at least the following attributes as being associated with the formulation defined in Example 3: decreased skin wrinkles;
improvement in skin tone; increased skin firmness; and increased skin hydration.
It was determined that the formulation/mixture of Example 3 was absorbed by human skin.
Date Recue/Date Received 2021-09-02 Example 4. Composition with acidified fucoidan and beta glucan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 4.
Table 4. Components of an embodiment of the invention Sequence No. Component Amount (%
by weiaht) Aqueous Aloe barbedensis leaf extract 45 Distilled water 40.8 Tourmaline, volcanic obsidian 0.2 Glycolic and salicylic acids (ratio 8:1) (neutralized 6 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Fucoidan, beta glucan, Ulva lactuta (ratio: 5:5:1.5) 4 II Aqueous extract of CameNa sinensis, Centella 1.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (these extracts are present in equal amounts) Ill Complex of butylene glycol, allantoin, 2.5 phenoxyethanol, caprylyl glycol, sorbic acid (ratio:
1.5:0.5:0.25:0.25:0.25) The methodology employed in producing the composition using the amounts described in Table 4 is generally as follows.
Tourmaline and volcanic obsidian (source: Soliance) were dissolved into distilled water. Ulva lactuta, fucoidan (source: Marinova), beta glucan (source: Arch Personal Care) were added to above polarized water and mixture was heated to approximately 80 degrees Celsius and stirred for approximately 40 minutes.
Neutralized glycolic acid, as disclosed herein, was added to the above mixture, and stirred at approximately 80 degrees Celsius for approximately another 30 minutes.
Thereafter, Aloe barbedensis leaf extract (source: Tri-K) and aqueous extract of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko Date Recue/Date Received 2021-09-02 biloba (source: Active Organics) as detailed in the corresponding Table, were added and the entire mixture was stirred for approximately another 10 minutes.
At this stage any of a variety of surfactants can be incorporated to constitute an effective cleansing composition focusing on the above key ingredients.
Thereafter, butylene glycol, allantoin, phenoxyethanol, caprylyl glycol, sorbic acid (source: International Specialty Products) were added and the entire mixture was stirred for approximately another 10 minutes. The entire mixture was then cooled to room temperature. The mixture developed in Example 4 is a homogenous mixture.
Testing efficacy of Example 4 To test the efficacy of the mixture described in Example 4, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 4 improved the appearance of the skin of human subjects.
Serving as an example, MT, a male under the age of 30 used the formulation defined in Example 4. Prior to using the formulation of Example 4, MT had exhibited slightly acned skin that included a small amount of wrinkling. On day 0, MT
began applying the formulation defined in Example 4 to his skin using a cotton pad soaked in the formulation defined in Example 4. After one week, MT described his skin as appearing clearer with a less dull appearance. After two weeks, MT described his skin as having less breakouts of acne. After one month, MT described his skin as appearing brighter, clearer, and tighter. MT identified at least the following attributes as being associated with the formulation defined in Example 4: increased skin firmness; improved skin tone, and smoother and brighter skin appearance.
It was determined that the formulation/mixture of Example 4 was absorbed by human skin.
Example 5. Composition with acidified fucoidan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 5.
Date Recue/Date Received 2021-09-02 Table 5. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Glycolic and salicylic acids (ratio 8:1) (neutralized 12.8 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Tourmaline (0.15%) and volcanic obsidian (0.5%) 0.2 Kaolin and bentonite (ratio of these products: 26 0.6:0.3) Beta glucan (yeast and specified medicinal fungi 10 extract combined in a 1:1 ratio) in a 1:1 ratio with fucoidan complex, Ulva lactuta [5:5:1.5]
Undaria pinnatifida 4 Diatomite silica, n-acetyl glucosamine, hydrolyzed 2.5 pearl nacre, and chitosan (ratio of these products:
1:1:0.25:0.25) Aqueous Aloe barbedensis leaf extract 10 Echinacea augustifolia and Panax ginseng (ratio of 2 these products: 1:1) Stearic acid, cetearyl alcohol, and ceteareth 20 30 complex in equal parts (each of these products is added at an equal amount) Complex of phenoxyethanol, caprylyl glycol, sorbic 2.5 acid (ratio of these products: 1.5:0.5:0.5) Date Recue/Date Received 2021-09-02 The methodology employed in producing the composition using the amounts described in Table 5 is generally as follows.
Method Sequence No. I
In a first mixture, neutralized glycolic acid (source: Dupont or Spectrum Chemical), salicylic acid (source: Spectrum), tourmaline and volcanic obsidian (source:
Soliance) was heated in a stainless steel container to approximately 85 degrees Celsius.
The seaweed complex consisting of ulva lactuta (source: Unipex Innovations), beta glucan fucoidan complex (source: Biothera, Marinova), and Undaria pinnatifida (source:
Marinova) were added to the heated glycolic acid mixture. The combined mixture was agitated for approximately 30 minutes. Diatomite silica, n-acetyl glucosamine, hydrolyzed pearl nacre (source: Rita Corp.), and chitosan (source: Alfa Chem) were added to the above mixture.
Kaolin and bentonite (source: Xenex Labs; Vancouver, British Columbia] were separately mixed and added to the above mixture. While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K Industries), Echinacea augustifolia, and Panax ginseng (source: Active Organics) were added.
Method Sequence No. 2 Thereafter, and separately, stearic acid, cetearyl alcohol, and ceteareth 20 complex (source: Hallstar Corp.) were heated to approximately 75 degrees C, stirring for approximately 60 minutes.
Method Sequence No. 3 In a further mixture, phenoxyethanol, caprylyl glycol, and sorbic acid (source:
International Specialty Products) were combined to make a complex. Thereafter, this complex was added to the stearic acid complex described above, the stearic complex having been maintained at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius. Thereafter, the mixture developed from Method Sequence No. 1 (see above) was added to the mixture. The mixture was allowed to cool to approximately 20 degrees Celsius. The mixture developed in Example 5 is a homogenous mixture.
Date Recue/Date Received 2021-09-02 In a modification to the above, the beta glucan complex can be present as 12%
of the formulation instead of 10% as described in Table 5. Further, the Undaria pinnatifida can be present at 2% instead of 4% as described in Table 5.
Testing efficacy of Example 5 To test the efficacy of the mixture described in Example 5, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 5 improved the appearance of the skin of human subjects.
Serving as an example, JT, a female between the age of 30-40, used the formulation defined in Example 5. Prior to using the formulation of Example 5, JT had exhibited skin conditions that included acne and rough spots. On day 0, JT
began using an amount approximately equivalent to the size of a quarter and used approximately twice that amount twice a week. After one week, JT described her skin as having fewer breakouts of acne. After two weeks, JT described her skin as being clearer.
After one month, JT described her skin as appearing smoother. JT identified at least the following attributes as being associated with the formulation defined in Example 5:
increased smoothness of the skin, increased luminosity of the skin, increased firmness of the skin, increased tautness of the skin, and less irritation and skin-associated inflammation.
It was determined that the formulation/mixture of Example 5 was absorbed by human skin.
Example 6. Serum composition The methodology employed in producing the non-acidified serum composition using the amounts described in Table 6 is generally as follows.
Method Sequence No.]
Polarized water was developed by adding tourmaline and obsidian (source:
Soliance) to the distilled water. The seaweed complex consisting of phytoplankton extract (source: Canadian Pacific Phytoplankton), Fucus vesiculosus extract (source:
Xenex), ecklonia cava (source: JP Renew; San Francisco, California) was dissolved into one-half of the distilled water, heated to approximately 85 degrees Celsius.
The combined Date Recue/Date Received 2021-09-02 mixture was then stirred for approximately 45 minutes to 60 minutes. The beta glucan and fucoidan complex (source: Biothera, Marinova) and vegetal astaxanthin (source:
Unipex Innovations) was dissolved in the seaweed complex-distilled water mixture (previously described above). The heated mixture continued to Table 6. Components of an embodiment of the invention SEQUENCE INGREDIENT AMOUNT
Distilled water 40.8 Tourmaline, volcanic obsidian [1:.5] 0.2 Phytoplankton extract, Fucus vesiculosus extract, 6 EckIonia cava complex [1:1:.5:.5]
Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio), fucoidan, vegetal astaxanthin complex [5:5:1.5]
Hydrolyzed pearl nacre, chitosan [1:.5] 1.5 Phospholipids, sodium pCA [1:.5] 8 II Magnesium ascorbyl phosphate, tocotrienol, 25 niacinamide, tocopheryl acetate, ergocalciferol complex [10:1%5%5%5]
II Camellia sinensis, epigallocatechin (EGCG), ellagic 4 acid,l-arginine [2:1:.5:.5]
Ill Complex of butylene glycol, phenoxyethanol, caprylyl 3.5 glycol, sorbic acid, peg8/SMDI copolymer [2:1 :.5:.5:.5]
Ill Sodium citrate, tetrasodium EDTA [1:.5] 3 be stirred while the temperature was maintained at approximately 85 degrees Celsius for a minimum of approximately 30 minutes. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, hydrolyzed pearl nacre (source:
Active Concepts) and chitosan (source: Alfa Chem) were added to the cooled mixture.
Thereafter, phospholipids (source: Arch Personal Care) and sodium hyaluronate (source: Tri-K
Industries) were added to the cooled mixture.
Date Recue/Date Received 2021-09-02 Method Sequence No. 2:
In a further mixture, a complex comprising magnesium ascorbyl phosphate (source: Optima Specialty; Huntington, Connecticut) with tocotrienol, niacinamide, tocopheryl acetate, ergocalciferol (source: Arch Personal Care) was mixed into the remaining one-half of polarized water and heated to approximately 70 degrees Celsius.
This mixture was allowed to dissolve in the polarized water for one hour.
Thereafter, Camellia sinensis (source: Active Organics), epigallocatechin (EGCG) (source:
DSM
Nutritional Products; Belvedere, New Jersey), ellagic acid (source: DSM), and 1-arginine (source: Alpha Chem) were added to the ascorbyl polypeptide ¨ tocotrienol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer (source: International Specialty Products) are combined in the ratio specified in the Table 6 above to make a complex. Thereafter, this complex was added to the magnesium ascorbyl ¨ tocotrienol mixture described above in Method Sequence No. 2, the magnesium ascorbyl ¨ tocotrienol having been maintained at approximately 70 degrees Celsius. Thereafter sodium citrate and tetrasodium EDTA (source: Xenex) was added.
The mixture was then stirred for approximately 15 minutes, while maintaining at approximately 70 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius. Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius. The mixture developed in Example 6 is a homogenous mixture.
In a modification to the above, the phytoplankton extract can be present as 2%
of the formulation instead of 6% as described in Table 6. Further, the bet glucan complex can be present at 12% instead of 8% as described in Table 6.
Testing efficacy of Example 6 To test the efficacy of the mixture described in Example 6, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 6 improved the appearance of the skin of human subjects.
Date Recue/Date Received 2021-09-02 Serving as an example, TK, a female over the age of 40 used the formulation defined in Example 6. Prior to using the formulation of Example 6, TK had exhibited sensitive skin conditions and her skin was sun-damaged. On day 0, TK began using an amount equivalent to the size of a dime of the formulation in Example 6 on a daily basis.
After one week, TK described her skin as appearing more refreshed. After two weeks, TK
described her skin as appearing less irritated or red as compared with before use of the formulation. After one month, TK described her skin as appearing clearer, and more firm with less wrinkle lines. TK identified at least the following attributes as being associated with the formulation defined in Example 6: increased smoothness (diminished appearance of wrinldes); increased luminosity; increased firmness; increased tautness;
and less irritation and skin-associated inflammation.
It was determined that the formulation/mixture of Example 6 was absorbed by human skin.
While specific embodiments of the invention have been described and illustrated, such embodiments should be considered illustrative of the invention only and not as limiting the invention as construed in accordance with the accompanying claims.
Date Recue/Date Received 2021-09-02
An amino acid residue may be generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following Table A.
Amino acids comprising the peptides described herein will be understood to be in the L- or D- configuration.
Amino acids described herein, may be modified by methylation, amidation, acetylation or substitution with other chemical groups which may change the circulating half-life of the peptide without adversely affecting their biological activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention.
Nonstandard amino acids may occur in nature, and may or may not be genetically encoded.
Examples of genetically encoded nonstandard amino acids include selenocysteine, sometimes incorporated into some proteins at a UGA codon, which may normally be a stop codon, or pyrrolysine, sometimes incorporated into some proteins at a UAG codon, which may normally be a stop codon. Some nonstandard amino acids that are not genetically encoded may result from modification of standard amino acids already incorporated in a peptide, or may be metabolic intermediates or precursors, for example.
Examples of nonstandard amino acids include 4-hydroxyproline, 5-hydroxylysine, methyllysine, gamma-carboxyglutamate, desmosine, selenocysteine, ornithine, citrulline, lanthionine, 1-aminocyclopropane-1 -carboxylic acid, gamma-aminobutyric acid, camitine, sarcosine, or N-formylmethionine. Synthetic variants of standard and non-standard amino acids are also known and may include chemically derivatized amino acids, amino acids labeled for identification or tracking, or amino acids with a variety of side groups on the alpha carbon. Examples of such side groups are known in the art and may include aliphatic, single aromatic, polycyclic aromatic, heterocyclic, heteronuclear, amino, alkylamino, carboxyl, carboxamide, carboxyl ester, guanidine, amidine, hydroxyl, alkoxy, mercapto-, alkyhnercapto-, or other heteroatom-containing side chains. Other synthetic amino acids may include alpha-amino acids, non-alpha Date Recue/Date Received 2021-09-02 Table A. Nomenclature and abbreviations of the 20 standard L-amino acids commonly found in naturally occurring peptides Full name Three-letter abbreviation .. One-letter abbreviation Alanine Ala A
Cysteine Cys Aspartic acid Asp Glutamic acid Glu Phenylalanine Phe Glycine Gly Histidine His Isoleucine Ile Lysine Lys Leucine Leu Methionine Met Asparagine Asp Proline Pro Glutamine Gin Arginine Arg Serine Ser Threonine Thr Valine Val V
Tryptophan Trp Tyrosine Tyr Date Recue/Date Received 2021-09-02 amino acids such as beta-amino acids, des-carboxy or des-amino acids.
Synthetic variants of amino acids may be synthesized using general methods known in the art, or may be purchased from commercial suppliers, for example RSP Amino Acids LLC (Shirley, MA).
Additionally, the composition may include an amount of a mineral and its salt.
The mineral may be calcium, magnesium, manganese, or zinc. The mineral chosen is not limited to the aforementioned minerals. The composition may include an amount of a base, including but not limited to, a soluble plant butter, a soluble plant wax, an anhydrous plant based cholesterol base, a phycocolloid gel base, a prepared polyethylene glycol ointment base, or a prepared carbomer gel base. The composition may include an amount of a marine component including, but not limited to, any one or more of the following: an Enteromorpha species, a Porphyra species, a Chrondus species, a Laminares species, a kelp species or a Fucals species. The marine component or seaweed utilized in the composition can be selected from the group consisting of brown algae, red algae and green algae. Further the marine component or seaweed utilized in the composition can be selected by pre-determining the content of any one of the following in the marine component: natural amino acids, fatty acids and their glycosyl derivatives, sterols, natural antimicrobials, ursolic acid, or mono / polysaccharides. Methods for analyzing the above are known in the art and include but are not limited to the techniques disclosed in Sanchez-Machado et al. (2004) BMC 18(3):183-90.
Further, the composition may include an amount of an anti-inflammatory agent.
The anti-inflammatory agent may include, but is not limited to, any one or more of the following: Glycyrrhiza glabria, Boswellia serrate, Curcuma longa, turmeric, Arnica montana, silymarin, water melon, calendula, eidelweiss, or ginger.
The composition may include an amount of a surfactant. The surfactant may be amphoteric. They surfactant may be, but is not limited to, cocomidopropyl betaine. The surfactant may be non-ionic. The surfactant may be, but is not limited to, cocoglucoside or coco polyglucose. The surfactant may be cationic. The surfactant may be, but is not limited to, lauryl dimoniumhydrolysed collagen.
The composition may include an amount of a percutaneous penetration enhancer including, but not limited to, any one or more of the following: polyethylene glycol or oleic acid. The composition may include an amount of a preservative enhancer including, but not limited to, any one or more of the following: ethylhexyl glycerin, benzethonym Date Recue/Date Received 2021-09-02 chloride, or a hydantoin/PCB blend. Further, the composition may include an amount of a vasodilator including, but not limited to, any one of the following: adenosine triphosphate or liposomal 1 arginine.
Further, the composition may include an amount of a vasoconstrictor including, but not limited to, any one or more of the following: sea buckthorn, milk thistle, or marshmallow root. Additionally, the composition may include an amount of a whitening agent. The composition may include an amount of a tyrosinase inhibitor including, but not limited to, an inhibitor selected from the Glycyrrhiza species. The tyrosinase inhibitor may include, but is not limited to, a favnoid, a polyphenol, an isoflavon, or a coumarin.
Further, the composition may include an amount of octadecnedioic acid or chalcones or a combination thereof.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of skill in the art in light of teachings of this invention that changes and modification may be made thereto without departing from the spirit or scope of the invention.
EXAMPLES
Example 1. Composition with acidified fucoidan, beta glucan, and ascorbyl polypeptide In accordance with an embodiment of the present invention, a composition is described having the components shown in Table 1 below. The methodology employed in producing the composition using the amounts described in Table 1 below is generally as follows.
Method Sequence No. 1 In a first mixture, neutralized glycolic and salicyclic acid solution (source:
Spectrum Chemical; Gardena, California) was heated in a stainless steel container to approximately 85 degrees Celsius. The seaweed complex consisting of Ulva lactuta, Alteromonas maclodeii, and astaxanthin (source: Unipex Innovations, Mississauga, Ontario) was added to the heated glycolic acid mixture. The combined mixture was mixed for approximately 45 to 60 minutes.
Date Recue/Date Received 2021-09-02 Table 1. Components of an embodiment of the Invention Sequence No. Component Amount (%
by weight) Glycolic acid-salicylic acid solution (ratio: 8:1) 10 (neutralized with ammonium hydroxide; ammonium glycolate, sodium lactate can also be added to obtain a preferable pH of -4) Seaweed complex containing Ulva lactuta, 5.5 Alteromonas maclodeii and Astaxanthin (ratio:
7:1.5:1.5) Distilled Water 20.8 Tourmaline (0.15%) and volcanic obsidian (0.05%) 0.2 Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio) and fucoidan complex (beta glucan and fucoidan are present in a 1:1 ratio) Aqueous Aloe barbadensis extract 10 Hydrolyzed pearl nacre (1.5%) and chitosan (0.5%) 2.5 Phospholipids 10 Glyceryl stearate, stearic acid, cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex (each of these products is added at an equal amount) Ascorbyl polypeptide, tocotrienol, tocopheryl 6 acetate, ergocalciferol, niacinamide complex (ratio of these products: 3:1:1:1:1:1) Aqueous extract of Camellia sinensis, Centella 1.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (each of these products is added at an equal amount) Complex of butylene glycol, phenoxyethanol, 2.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer (these products are added at the following ratio: 1.5:
0.5 : 0.25 : 0.25 : 0.25) Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 A polarized water was developed by adding tourmaline and obsidian (source:
Soliance; Paris, France) to the distilled water. The beta glucan (source:
Biothera; Eagen, Minnesota) and fucoidan (source: Marinova; Cambridge, Tasmania, Australia) complex was dissolved in one-third of the polarized water. The dissolved beta glucan-fucoidan complex was added to the glycolic acid mixture (previously described above) and the entire solution was maintained at approximately 85 degrees Celsius for approximately 30 minutes. While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K Industries; Northvale, New Jersey) was added and the entire mixture was allowed to cool for approximately 30 minutes. Thereafter, hydrolyzed pearl nacre (source:
Active Concepts; Lincolnton, North Carolina) and chitosan (source: Alfa Chem;
Kings Point, New York) were added to the cooled mixture. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, phospholipids (source:
Arch Personal Care; Norwalk, Connecticut) were added to the cooled mixture.
Method Sequence No. 2 In a further mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.; Chicago, Illinois) were heated to 75 degrees Celsius in a 200 kg stainless steel vat. The mixture was mixed by continuous stirring for approximately 60 minutes.
Separately, the remaining two-thirds of polarized water (as described above) was used to dissolve the ascorbyl polypeptide-tocotrienol complex (source: Arch Personal Care). The ascorbyl polypeptide-tocotrienol complex was allowed to dissolve in the polarized water for approximately one hour. Thereafter, aqueous extracts of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko biloba (source: Active Organics; Louisville, Texas) were added to the ascorbyl polypeptide ¨ tocotrienol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer were added at the ratio described above to make a complex (source: International Specialty Products; Mississauga, Ontario). Thereafter, this complex was added to the glyceryl stearate complex mixture described above, the glyceryl stearate Date Recue/Date Received 2021-09-02 complex having been maintained at approximately 75 degrees Celsius.
Thereafter, the ascorbyl polypeptide-tocotrienol complex, which had previously been mixed with the aqueous extracts described above, was added and agitation of the mixture continued at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius.
Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 1 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 1.5% of the formulation instead of 5.5% as described in Table 1. Further, the beta glucan and fucoidan complex can be present as 12% of the formulation instead of 8% as described in Table 1.
Testing efficacy of Example 1 To test the efficacy of the mixture described in Example 1, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that following application of the mixture described in Example 1, the human subjects exhibited improved appearance of their skin.
Serving as an example, JT, a female under the age of 30 years of age, used the formulation defined in Example 1. Prior to using the formulation of Example 1, JT had exhibited sensitive skin and a tendency to have acne breakouts. JT also described numerous fine lines being visible in her forehead region. On day 0, JT began using an amount approximately equivalent to the size of a quarter and used approximately that amount each morning on her skin. After one week, JT described her skin as being brighter and with an improved complexion. After two weeks, JT described that the fine lines on her skin were blurred. After one month, JT described that her skin had less breakouts and was very smooth. JT identified at least the following attributes as being associated with the formulation defined in Example 1: increased smoothness and brightness of the skin, decreased lines on JT's forehead, and decreased breakouts of acne. Further, JT
identified the formulation of Example 1 as being associated with decreased dryness of the skin.
It was determined that the formulation/mixture of Example 1 was absorbed by human skin.
Date Recue/Date Received 2021-09-02 Example 2. Composition with non-acidified fucoidan and beta glucan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 2. The methodology employed in producing the composition using the amounts described in Table 2 is generally as follows.
Method Sequence No. I
In a first mixture, a polarized water was developed by adding tourmaline and obsidian (source: Soliance) to the distilled water. The seaweed complex consisting of Ulva lactuta, Astaxanthin, Alteromonas maclodeii (source: Unipex Innovations;
Quebec City, Quebec) was dissolved into one half of the polarized water. The mixture was maintained at approximately 85 degrees Celsius. While maintaining the temperature, the mixture was stirred for approximately 45 minutes to 60 minutes. Thereafter, beta glucan (source: Biothera) and fucoidan (source: Marinova) complex were dissolved in the seaweed complex-distilled water mixture. This mixture was maintained at approximately 85 degrees Celsius and the mixture was stirred for at least approximately 30 minutes.
Thereafter, while maintaining the mixing of the mixture, the aqueous Aloe barbedensis leaf extract (source: Tri K Industries) was added and the entire mixture was allowed to cool for approximately 30 minutes.
Therafter, hydrolyzed pearl nacre (source: Rita Corp.; Crystal Lake, Illinois) and chitosan (source: Alfa Chem), acetyl glucosomine (source: Alfa Chem), n-acetyl camatine (source: Alfa Chem), alpha lipoic acid (source: Alfa Chem), and 1-arginine (source: Alfa Chem) were added to the cooled mixture. The cooled mixture was further cooled to approximately 30 degrees Celsius. Thereafter, phospholipids (source: Arch Personal Care) and sodium hyaluronate (source: Tri-K Industries) were added to the mixture.
Date Recue/Date Received 2021-09-02 Table 2. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Distilled water 18.8 Tourmaline (0.15%) and volcanic obsidian (0.05%) 0.2 Seaweed complex containing Ulva lactuta, 10 Astaxanthin, Alteromonas maclodeii (ratio of these products: 7:1.5:1.5) Beta glucan (yeast and specified medicinal fungi 10 extract combined in a 1:1 ratio) and fucoidan complex (beta glucan and fucoidan are present in a 1:1 ratio) Aqueous Aloe barbedensis leaf extract 12 Hydrolyzed pearl nacre and chitosan (ratio of these 1.5 products: 1.5:1) N-acetyl carnitine, alpha lipoic acid, and I-arginine 3.5 (ratio of these products: 1.5:1.5:0.5) Phospholipids and sodium hyaluronate (ratio of these 8 products: 4:1) II Glyceryl stearate, stearic acid, cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex (each of these products is added at an equal amount) II Ascorbyl polypeptide, tocotrienol, tocopheryl acetate, 5 ergocalciferol, ferulic acid, niacinamide complex (ratio of these products: 3:1:0.5:0.5:0.5:0.5) II Glycine sofa, Rumex crispis, Vitis vinifera, hinokitiol 2 (beta thujaplicin) (each of these products is added at an equal amount) II Aqueous extract of Camellia sinensis, Centella 2.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (each of these products is added at an equal amount) Ill Complex of butylene glycol, phenoxyethanol, caprylyl 3.5 glycol, sorbic acid, peg8/SMDI copolymer (ratio of these products: 1.5:.05:0.25:0.25:0.25) III Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 Method Sequence No. 2 In a second mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, isopropyl palmitate complex (all from source: Hallstar Corp.) were heated to 75 degrees Celsius in a 200 kg. stainless steel vat. The mixture was mixed by continuous stirring for approximately 60 minutes.
Separately, ascorbyl polypeptide, tocotrienol, tocopheryl acetate, ergocalciferol, ferulic acid, and niacinamide (all from source: Arch Personal Care) were dissolved into the second half of the polarized water (as described above) over a period of approximately one hour. Thereafter, Glycine sofa, Rumex crispis, Vitis vinifera, and hinokitiol (beta thujaplicin) (all from source: Active Organics); and aqueous extracts of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko biloba (all from source: Active Organics) were added to the ascorbyl polypeptide-tocotrienol mixture.
Method Sequence No. 3 Butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid and peg8/SMDI
copolymer (all from source: International Specialty Products) were combined to form a complex.
Thereafter, the complex was added to the glyceryl stearate mixture described above, while the glyceryl stearate mixture was maintained at approximately 75 degrees Celsius.
Thereafter, the ascorbyl polypeptide-tocotrienol mixture described above was added and agitation of the mixture continued at approximately 75 degrees Celsius. The entire mixture was then cooled to approximately 30 degrees Celsius. Thereafter, the mixture developed above in Method Sequence No. 1 was added. Thereafter, the mixture was allowed to cool to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 2 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 4% of the formulation instead of 10% as described in Table 2. Further, the beta glucan and fucoidan complex can be present as 16% of the formulation instead of 10% as described in Table 2.
Date Recue/Date Received 2021-09-02 Testing efficacy of Example 2 To test the efficacy of the mixture described in Example 2, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 2 improved the appearance of the skin of human subjects.
Serving as an example, MJ, a female over the age of 40 years of age, used the formulation defined in Example 2. Prior to using the formulation of Example 2, MJ had exhibited under-eye skin that was puffy, sensitive and quite dry. On day 0, MJ
began using an amount approximately equivalent to the size of a dime and used approximately that amount each morning and night on her skin. After one week, MJ described her under-eye skin as being less puffy. After two weeks, MJ again described her under-eye skin as being less puffy. After one month, MJ described her under-eye skin as bein tighter looking and having fewer small wrinldes such that the skin appeared to be smoother in appearance. MJ identified at least the following attributes as being associated with the formulation defined in Example 2: decreased skin wrinldes; improvement in skin tone;
increased skin firmness; and increased skin hydration.
It was determined that the formulation/mixture of Example 2 was absorbed by human skin.
Example 3. Composition with acidified fucoidan, beta glucan and retinol In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 3. The methodology employed in producing the composition using the amounts described in Table 3 is generally as follows.
Method Sequence No.
In a first mixture, neutralized glycolic and salicylic acid solution (source:
Dupont or Spectrum Chemical) was heated in a stainless steel container to approximately 85 degrees Celsius. The seaweed complex consisting of Date Recue/Date Received 2021-09-02 Table 3. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Glycolic and salicylic acids (ratio: 8:1) (neutralized 10 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Seaweed complex containing EckIonia cava, 5.5 Alteromonas maclodeii and Astaxanthin [ratio:
7:1.5:1.5]
Distilled water 14.8 Tourmaline (0.15%) and volcanic obsidian (0.5%) 0.2 Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio) in a 1:1 ratio with fucoidan complex Aqueous Aloe barbedensis leaf extract 10 Hydrolyzed pearl nacre (1.5%) and chitosan (1.0%) 2.5 Phospholipids 10 Glyceryl stearate, stearic acid, cetearyl alcohol, 20 ceteareth 20, isopropyl palmitate (each of these products is added at an equal amount) Tocotrienol, tocopheryl acetate, niacinamide, retinol 6 complex (ratio of these products: 3:1.5:1.5:0.5) Aqueous extract of Vitis vinifera, Chamomile 2.5 matricaria, Echinacea augustifolia, Panax ginseng, Glycine sofa, allantoin (each of these products is added at an equal amount) Complex of butylene glycol, phenoxyethanol, 2.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer (ratio of these products: 1.5:0.5:0.25:0.25:0.25) Aqueous superoxide dismutase liposomes 8 Date Recue/Date Received 2021-09-02 EckIonia cava, Alteromonas maclodeii, and Astaxanthin (source: Unipex Innovations) was added to the heated glycolic acid mixture. The combined mixture was mixed for approximately 45 to 60 minutes.
Polarized water was developed by adding tourmaline and obsidian (source:
Soliance) to the distilled water. The beta glucan and fucoidan complex (source: Active Concepts, Marinova) was dissolved in one-third of the polarized water. The dissolved beta glucan - fucoidan complex was added to the glycolic acid mixture (previously described above) and the entire solution continued to be stirred while the temperature was maintained at approximately 85 degrees Celsius for approximately 30 minutes.
While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K
Industries) was added and the entire mixture was allowed to cool for 30 minutes.
Thereafter, hydrolyzed pearl nacre (source: Rita Corp.) and chitosan (source:
Alfa Chem) were added to the cooled mixture. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, phospholipids (source: Arch Personal Care) were added to the cooled mixture.
Method Sequence No. 2 In a further mixture, glyceryl stearate, stearic acid, cetearyl alcohol, ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.) were heated to 75 degrees Celsius in a 200 kg. stainless steel vat. The mixture was mixed by continuous stirring for 60 minutes.
Separately, the remaining two-thirds of polarized water (as described above) was used to dissolve the tocotrienol ¨ retinol complex (source: Arch Personal Care). The tocotrienol ¨ retinol complex was allowed to dissolve in the polarized water for one hour.
Thereafter, aqueous extracts of Vitis vinifera, Chamomile matricaria, Echinacea augustifolia, Panax ginseng, Glycine sofa, and allantoin (source: Active Organics) were added to the tocotrienol ¨ retinol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer were combined to make a complex (source: International Specialty Products). Thereafter, this complex was added to the glyceryl stearate complex Date Recue/Date Received 2021-09-02 mixture described above, the glyceryl stearate complex having been maintained at 75 degrees Celsius. Thereafter, the ascorbyl polypeptide-tocotrienol complex, which had previously been mixed with the aqueous extracts described above, was added and agitation of the mixture continued at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius.
Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius and liposomal superoxide dismutase (source: Arch Personal Care) was added. The mixture developed in Example 3 is a homogenous mixture.
In a modification to the above, the seaweed complex can be present as 3.5% of the formulation instead of 5.5% as described in Table 3. Further, the beta glucan and fucoidan complex can be present as 10% of the formulation instead of 8% as described in Table 3.
Testing efficacy of Example 3 To test the efficacy of the mixture described in Example 3, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 3 improved the appearance of the skin of human subjects.
Serving as an example, CO, a female between the age of 30-40 years of age, used the formulation defined in Example 3. Prior to using the formulation of Example 3, CO
had exhibited oily skin that was prone to acne breakouts. Further, CO
described that her skin was rough, and that skin pores were visible. Further, CO described that her skin showed an appearance of acne scarring. On day 0, CO began using an amount approximately equivalent to the size of a dime and used approximately that amount each night on her skin. After one week, CO described her skin as having faded acne scarring.
After two weeks, CO described that her skin appeared to be more radiant and glowing in appearance. After one month, CO described her skin as being firmer and that the acne breakouts had stopped. CO identified at least the following attributes as being associated with the formulation defined in Example 3: decreased skin wrinkles;
improvement in skin tone; increased skin firmness; and increased skin hydration.
It was determined that the formulation/mixture of Example 3 was absorbed by human skin.
Date Recue/Date Received 2021-09-02 Example 4. Composition with acidified fucoidan and beta glucan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 4.
Table 4. Components of an embodiment of the invention Sequence No. Component Amount (%
by weiaht) Aqueous Aloe barbedensis leaf extract 45 Distilled water 40.8 Tourmaline, volcanic obsidian 0.2 Glycolic and salicylic acids (ratio 8:1) (neutralized 6 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Fucoidan, beta glucan, Ulva lactuta (ratio: 5:5:1.5) 4 II Aqueous extract of CameNa sinensis, Centella 1.5 asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba (these extracts are present in equal amounts) Ill Complex of butylene glycol, allantoin, 2.5 phenoxyethanol, caprylyl glycol, sorbic acid (ratio:
1.5:0.5:0.25:0.25:0.25) The methodology employed in producing the composition using the amounts described in Table 4 is generally as follows.
Tourmaline and volcanic obsidian (source: Soliance) were dissolved into distilled water. Ulva lactuta, fucoidan (source: Marinova), beta glucan (source: Arch Personal Care) were added to above polarized water and mixture was heated to approximately 80 degrees Celsius and stirred for approximately 40 minutes.
Neutralized glycolic acid, as disclosed herein, was added to the above mixture, and stirred at approximately 80 degrees Celsius for approximately another 30 minutes.
Thereafter, Aloe barbedensis leaf extract (source: Tri-K) and aqueous extract of Camellia sinensis, Centella asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko Date Recue/Date Received 2021-09-02 biloba (source: Active Organics) as detailed in the corresponding Table, were added and the entire mixture was stirred for approximately another 10 minutes.
At this stage any of a variety of surfactants can be incorporated to constitute an effective cleansing composition focusing on the above key ingredients.
Thereafter, butylene glycol, allantoin, phenoxyethanol, caprylyl glycol, sorbic acid (source: International Specialty Products) were added and the entire mixture was stirred for approximately another 10 minutes. The entire mixture was then cooled to room temperature. The mixture developed in Example 4 is a homogenous mixture.
Testing efficacy of Example 4 To test the efficacy of the mixture described in Example 4, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 4 improved the appearance of the skin of human subjects.
Serving as an example, MT, a male under the age of 30 used the formulation defined in Example 4. Prior to using the formulation of Example 4, MT had exhibited slightly acned skin that included a small amount of wrinkling. On day 0, MT
began applying the formulation defined in Example 4 to his skin using a cotton pad soaked in the formulation defined in Example 4. After one week, MT described his skin as appearing clearer with a less dull appearance. After two weeks, MT described his skin as having less breakouts of acne. After one month, MT described his skin as appearing brighter, clearer, and tighter. MT identified at least the following attributes as being associated with the formulation defined in Example 4: increased skin firmness; improved skin tone, and smoother and brighter skin appearance.
It was determined that the formulation/mixture of Example 4 was absorbed by human skin.
Example 5. Composition with acidified fucoidan In accordance with a further embodiment of the present invention, a composition is described having the components shown in Table 5.
Date Recue/Date Received 2021-09-02 Table 5. Components of an embodiment of the invention Sequence No. Component Amount (%
by weight) Glycolic and salicylic acids (ratio 8:1) (neutralized 12.8 with ammonium hydroxide; ammonium glycolate, and sodium lactate can also be added to obtain a preferable pH of -4) Tourmaline (0.15%) and volcanic obsidian (0.5%) 0.2 Kaolin and bentonite (ratio of these products: 26 0.6:0.3) Beta glucan (yeast and specified medicinal fungi 10 extract combined in a 1:1 ratio) in a 1:1 ratio with fucoidan complex, Ulva lactuta [5:5:1.5]
Undaria pinnatifida 4 Diatomite silica, n-acetyl glucosamine, hydrolyzed 2.5 pearl nacre, and chitosan (ratio of these products:
1:1:0.25:0.25) Aqueous Aloe barbedensis leaf extract 10 Echinacea augustifolia and Panax ginseng (ratio of 2 these products: 1:1) Stearic acid, cetearyl alcohol, and ceteareth 20 30 complex in equal parts (each of these products is added at an equal amount) Complex of phenoxyethanol, caprylyl glycol, sorbic 2.5 acid (ratio of these products: 1.5:0.5:0.5) Date Recue/Date Received 2021-09-02 The methodology employed in producing the composition using the amounts described in Table 5 is generally as follows.
Method Sequence No. I
In a first mixture, neutralized glycolic acid (source: Dupont or Spectrum Chemical), salicylic acid (source: Spectrum), tourmaline and volcanic obsidian (source:
Soliance) was heated in a stainless steel container to approximately 85 degrees Celsius.
The seaweed complex consisting of ulva lactuta (source: Unipex Innovations), beta glucan fucoidan complex (source: Biothera, Marinova), and Undaria pinnatifida (source:
Marinova) were added to the heated glycolic acid mixture. The combined mixture was agitated for approximately 30 minutes. Diatomite silica, n-acetyl glucosamine, hydrolyzed pearl nacre (source: Rita Corp.), and chitosan (source: Alfa Chem) were added to the above mixture.
Kaolin and bentonite (source: Xenex Labs; Vancouver, British Columbia] were separately mixed and added to the above mixture. While maintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract (source: Tri K Industries), Echinacea augustifolia, and Panax ginseng (source: Active Organics) were added.
Method Sequence No. 2 Thereafter, and separately, stearic acid, cetearyl alcohol, and ceteareth 20 complex (source: Hallstar Corp.) were heated to approximately 75 degrees C, stirring for approximately 60 minutes.
Method Sequence No. 3 In a further mixture, phenoxyethanol, caprylyl glycol, and sorbic acid (source:
International Specialty Products) were combined to make a complex. Thereafter, this complex was added to the stearic acid complex described above, the stearic complex having been maintained at approximately 75 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius. Thereafter, the mixture developed from Method Sequence No. 1 (see above) was added to the mixture. The mixture was allowed to cool to approximately 20 degrees Celsius. The mixture developed in Example 5 is a homogenous mixture.
Date Recue/Date Received 2021-09-02 In a modification to the above, the beta glucan complex can be present as 12%
of the formulation instead of 10% as described in Table 5. Further, the Undaria pinnatifida can be present at 2% instead of 4% as described in Table 5.
Testing efficacy of Example 5 To test the efficacy of the mixture described in Example 5, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 5 improved the appearance of the skin of human subjects.
Serving as an example, JT, a female between the age of 30-40, used the formulation defined in Example 5. Prior to using the formulation of Example 5, JT had exhibited skin conditions that included acne and rough spots. On day 0, JT
began using an amount approximately equivalent to the size of a quarter and used approximately twice that amount twice a week. After one week, JT described her skin as having fewer breakouts of acne. After two weeks, JT described her skin as being clearer.
After one month, JT described her skin as appearing smoother. JT identified at least the following attributes as being associated with the formulation defined in Example 5:
increased smoothness of the skin, increased luminosity of the skin, increased firmness of the skin, increased tautness of the skin, and less irritation and skin-associated inflammation.
It was determined that the formulation/mixture of Example 5 was absorbed by human skin.
Example 6. Serum composition The methodology employed in producing the non-acidified serum composition using the amounts described in Table 6 is generally as follows.
Method Sequence No.]
Polarized water was developed by adding tourmaline and obsidian (source:
Soliance) to the distilled water. The seaweed complex consisting of phytoplankton extract (source: Canadian Pacific Phytoplankton), Fucus vesiculosus extract (source:
Xenex), ecklonia cava (source: JP Renew; San Francisco, California) was dissolved into one-half of the distilled water, heated to approximately 85 degrees Celsius.
The combined Date Recue/Date Received 2021-09-02 mixture was then stirred for approximately 45 minutes to 60 minutes. The beta glucan and fucoidan complex (source: Biothera, Marinova) and vegetal astaxanthin (source:
Unipex Innovations) was dissolved in the seaweed complex-distilled water mixture (previously described above). The heated mixture continued to Table 6. Components of an embodiment of the invention SEQUENCE INGREDIENT AMOUNT
Distilled water 40.8 Tourmaline, volcanic obsidian [1:.5] 0.2 Phytoplankton extract, Fucus vesiculosus extract, 6 EckIonia cava complex [1:1:.5:.5]
Beta glucan (yeast and specified medicinal fungi 8 extract combined in a 1:1 ratio), fucoidan, vegetal astaxanthin complex [5:5:1.5]
Hydrolyzed pearl nacre, chitosan [1:.5] 1.5 Phospholipids, sodium pCA [1:.5] 8 II Magnesium ascorbyl phosphate, tocotrienol, 25 niacinamide, tocopheryl acetate, ergocalciferol complex [10:1%5%5%5]
II Camellia sinensis, epigallocatechin (EGCG), ellagic 4 acid,l-arginine [2:1:.5:.5]
Ill Complex of butylene glycol, phenoxyethanol, caprylyl 3.5 glycol, sorbic acid, peg8/SMDI copolymer [2:1 :.5:.5:.5]
Ill Sodium citrate, tetrasodium EDTA [1:.5] 3 be stirred while the temperature was maintained at approximately 85 degrees Celsius for a minimum of approximately 30 minutes. The entire mixture was allowed to cool to approximately 30 degrees Celsius. Thereafter, hydrolyzed pearl nacre (source:
Active Concepts) and chitosan (source: Alfa Chem) were added to the cooled mixture.
Thereafter, phospholipids (source: Arch Personal Care) and sodium hyaluronate (source: Tri-K
Industries) were added to the cooled mixture.
Date Recue/Date Received 2021-09-02 Method Sequence No. 2:
In a further mixture, a complex comprising magnesium ascorbyl phosphate (source: Optima Specialty; Huntington, Connecticut) with tocotrienol, niacinamide, tocopheryl acetate, ergocalciferol (source: Arch Personal Care) was mixed into the remaining one-half of polarized water and heated to approximately 70 degrees Celsius.
This mixture was allowed to dissolve in the polarized water for one hour.
Thereafter, Camellia sinensis (source: Active Organics), epigallocatechin (EGCG) (source:
DSM
Nutritional Products; Belvedere, New Jersey), ellagic acid (source: DSM), and 1-arginine (source: Alpha Chem) were added to the ascorbyl polypeptide ¨ tocotrienol complex.
Method Sequence No. 3 In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid, and peg8/SMDI copolymer (source: International Specialty Products) are combined in the ratio specified in the Table 6 above to make a complex. Thereafter, this complex was added to the magnesium ascorbyl ¨ tocotrienol mixture described above in Method Sequence No. 2, the magnesium ascorbyl ¨ tocotrienol having been maintained at approximately 70 degrees Celsius. Thereafter sodium citrate and tetrasodium EDTA (source: Xenex) was added.
The mixture was then stirred for approximately 15 minutes, while maintaining at approximately 70 degrees Celsius. Thereafter, the entire mixture was cooled down to approximately 30 degrees Celsius. Thereafter, the mixture developed from Method Sequence No. 1 was added to the mixture. The mixture was allowed to cool down to approximately 20 degrees Celsius. The mixture developed in Example 6 is a homogenous mixture.
In a modification to the above, the phytoplankton extract can be present as 2%
of the formulation instead of 6% as described in Table 6. Further, the bet glucan complex can be present at 12% instead of 8% as described in Table 6.
Testing efficacy of Example 6 To test the efficacy of the mixture described in Example 6, the mixture was used by human subjects to determine the effect on the appearance of their skin. The results routinely showed that the mixture described in Example 6 improved the appearance of the skin of human subjects.
Date Recue/Date Received 2021-09-02 Serving as an example, TK, a female over the age of 40 used the formulation defined in Example 6. Prior to using the formulation of Example 6, TK had exhibited sensitive skin conditions and her skin was sun-damaged. On day 0, TK began using an amount equivalent to the size of a dime of the formulation in Example 6 on a daily basis.
After one week, TK described her skin as appearing more refreshed. After two weeks, TK
described her skin as appearing less irritated or red as compared with before use of the formulation. After one month, TK described her skin as appearing clearer, and more firm with less wrinkle lines. TK identified at least the following attributes as being associated with the formulation defined in Example 6: increased smoothness (diminished appearance of wrinldes); increased luminosity; increased firmness; increased tautness;
and less irritation and skin-associated inflammation.
It was determined that the formulation/mixture of Example 6 was absorbed by human skin.
While specific embodiments of the invention have been described and illustrated, such embodiments should be considered illustrative of the invention only and not as limiting the invention as construed in accordance with the accompanying claims.
Date Recue/Date Received 2021-09-02
Claims (113)
1. A cosmetic composition for applying to skin, the composition comprising:
a liquid, and dispersed in the liquid:
an amount of fucoidan;
an amount of beta glucan; and an amount of a marine extract, wherein the cosmetic composition improves the appearance of the skin to which the composition is applied.
a liquid, and dispersed in the liquid:
an amount of fucoidan;
an amount of beta glucan; and an amount of a marine extract, wherein the cosmetic composition improves the appearance of the skin to which the composition is applied.
2. The composition of claim 1, wherein the liquid is water.
3. The composition of claim 1, wherein the liquid is a glycolic acid-salicylic acid solution.
'15 4. The composition of claim 1, wherein the liquid is water and a glycolic acid-salicylic acid solution.
5. The composition of any one of claims 1-4, wherein the marine extract is any one or more of a green seaweed, a brown seaweed, an exopolysaccharide, or an algae.
6. The composition of claim 5, wherein the marine extract is Ulva lactuta, Alteromonas rnaclodeii, Astaxanthin, or Ecklonia cava.
7. The composition of any one of claims 5-6, wherein the composition includes an amount of tourmaline.
8. The composition of any one of claims 5-7, wherein the composition includes an amount of volcanic obsidian.
9. The composition of any one of claims 5-8, wherein the composition includes an amount of Aloe barbadensis.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
10. The composition of any one of claims 5-9, wherein the composition includes an amount of hydrolyzed pearl nacre.
11. The composition of any one of claims 5-10, wherein the composition includes an amount of chitosan.
12. The composition of any one of claims 5-11, wherein the composition includes an amount of a phospholipid.
13. The composition of any one of claims 5-12, wherein the composition includes an amount of glyceryl stearate.
14. The composition of any one of claims 5-13, wherein the composition includes an amount of stearic acid.
15. The composition of any one of claims 5-14, wherein the composition includes an amount of cetearyl alcohol.
16. The composition of any one of claims 5-15, wherein the composition includes an amount of ceteareth 20.
17. The composition of any one of claims 5-16, wherein the composition includes an amount of isopropyl palmitate.
18. The composition of any one of claims 5-17, wherein the composition includes an amount of ascorbyl polypeptide.
19. The composition of any one of claims 5-18, wherein the composition includes an amount of tocotrienol.
20. The composition of any one of claims 5-19, wherein the composition includes an amount of tocopheryl acetate.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
21. The composition of any one of claims 5-20, wherein the composition includes an amount of ergocalciferol.
22. The composition of any one of claims 5-21, wherein the composition includes an amount of niacinamide.
23. The composition of any one of claims 5-22, wherein the composition includes an amount of ferulic acid.
24. The composition of any one of claims 5-23, wherein the composition includes an amount of Camellia sinensis.
25. The composition of any one of claims 5-24, wherein the composition includes an amount of Centella asiatica.
26. The composition of any one of claims 5-25, wherein the composition includes an amount of Chamomile matricaria.
27. The composition of any one of claims 5-26, wherein the composition includes an amount of Echinacea augustzfolia.
28. The composition of any one of claims 5-27, wherein the composition includes an amount of Ginko biloba.
29. The composition of any one of claims 5-28, wherein the composition includes an amount of butylene glycol.
30. The composition of any one of claims 5-29, wherein the composition includes an amount of phenoxyethanol.
31. The composition of any one of claims 5-30, wherein the composition includes an amount of caprylyl glycol.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
32. The composition of any one of claims 5-31, wherein the composition includes an amount of sorbic acid.
33. The composition of any one of claims 5-32, wherein the composition includes an amount of peg8/SMDI copolymer.
34. The composition of any one of claims 5-33, wherein the composition includes an amount of superoxide dismutase liposomes.
35. The composition of any one of claims 5-34, wherein the composition includes an amount of N-acetyl carnitine.
36. The composition of any one of claims 5-35, wherein the composition includes an amount of alpha lipoic acid.
37. The composition of any one of claims 5-36, wherein the composition includes an amount ofl-arginine.
38. The composition of any one of claims 5-37, wherein the composition includes an amount of Glycine soja.
39. The composition of any one of claims 5-38, wherein the composition includes an amount of Rumex crispis.
40. The composition of any one of claims 5-39, wherein the composition includes an amount of Vitis vinfPra.
41. The composition of any one of claims 5-40, wherein the composition includes an amount of hinokitiol.
42. The composition of any one of claims 5-41, wherein the composition includes an amount of retinol.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
43. The composition of any one of claims 5-42, wherein the composition includes an amount of Panax ginseng.
44. The composition of any one of claims 5-43, wherein the composition includes an amount of allantoin.
45. The composition of any one of claims 5-44, wherein the composition includes an amount of kaolin.
46. The composition of any one of claims 5-45, wherein the composition includes an amount of bentonite.
47. The composition of any one of claims 5-46, wherein the composition includes an amount of Undaria pinnatifida.
48. The composition of any one of claims 5-47, wherein the composition includes an amount of diatomite silica.
49. The composition of any one of claims 5-48, wherein the composition includes an amount of n-acetyl glucosamine.
50. The composition of any one of claims 5-49, wherein the composition includes an amount of phytoplankton.
51. The composition of claim 50, wherein the composition includes an amount of Skeletonema.
52. The composition of claim 50, wherein the composition includes an amount of Thalassiosira.
53. The composition of claim 50, wherein the composition includes an amount of Chaetoceros.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
54. The composition of any one of claims 5-53, wherein the composition includes an amount of Fucus vesiculosus.
55. The composition of any one of claims 5-54, wherein the composition includes an amount of sodium pCA.
56. The composition of any one of claims 5-55, wherein the composition includes an amount of magnesium ascorbyl phosphate.
57. The composition of any one of claims 5-56, wherein the composition includes an amount of epigallocatechin (EGCG).
58. The composition of any one of claims 5-57, wherein the composition includes an amount of ellagic acid.
59. The composition of any one of claims 5-58, wherein the composition includes an amount of sodium citrate.
60. The composition of any one of claims 5-59, wherein the composition includes an amount of tetrasodium EDTA.
61. The composition of any one of claims 5-60, wherein the composition includes an amount of an emollient.
62. The composition of any one of claims 5-61, wherein the composition includes an amount of a sunscreen.
63. The composition of claim 62, wherein the sunscreen is an organic sunscreen.
64. The composition of claim 62, wherein the sunscreen is an inorganic sunscreen.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
65. The composition of any one of claims 5-64, wherein the composition includes an amount of a silicone surfactant.
66. The composition of claim 65, wherein the silicone surfactant is cyclomethicone or dimethicone copolyol.
67. The composition of any one of claims 5-66, wherein the composition includes an amount of a preservative.
68. The composition of claim 67, wherein the preservative is methylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropyl biguamide.
69. The composition of any one of claims 5-68, wherein the composition includes an amount of an aqueous botanical antioxidant.
70. The composition of claim 69, wherein the aqueous botanical antioxidant is hydroxytyrosol, rutin, silymarin, turmeric, genistein, apple, green coffee, quercetin, or rosemary.
71. The composition of any one of claims 5-70, wherein the composition includes an amount of a humectant.
72. The composition of claim 71, wherein the humectant is a glycerol, a sorbitol, or a polyol.
73. The composition of any one of claims 5-72, wherein the composition includes an amount of a thickener.
74. The composition of claim 73, wherein the thickener is a cosmetic gum.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
75. The composition of claim 74, wherein the cosmetic gum is alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester, modified potato starch, or pectin.
76. The composition of any one of claims 5-75, wherein the composition includes an amount of an oligomer.
77. The composition of claim 76, wherein the oligomer is iso-olefin, isodecane, hydrogenated polybutene, hydrogenated polydecene, polycaprolactone, fibronectin or polyethylene glycol.
78. The composition of any one of claims 5-77, wherein the composition includes an amount or combination of an arnino acid.
79. The composition of claim 78, wherein the amino acid is in its natural form.
80. The composition of claim 79, wherein the amino acid is a synthetic amino acid.
81. The composition of any one of claims 5-80, wherein the composition includes an amount of a mineral and its salt.
82. The composition of claim 81, wherein the mineral is calcium, magnesium, manganese, or zinc.
83. The composition of any one of claims 5-82, wherein the composition includes an amount of a base.
84. The composition of claim 83, wherein the base is a soluble plant butter, a soluble plant wax, an anhydrous plant based cholesterol base, a phycocolloid gel base, a prepared polyethylene glycol ointment base, or a prepared carbomer gel base.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
85. The composition of any one of claims 5-84, wherein the composition includes an amount of a marine component.
86. The composition of claim 85, wherein the marine component is an Enteromorpha species, a Porphyra species, a Chrondus species, a Laminares species, a kelp species or a Fucals species.
87. The composition of claim 85, wherein the marine component is a brown algae, a red algae, or a gfeen algae.
88. The composition of any one of claims 85-86, wherein the selection of the marine component is made by pre-determining the content of any one of the following in the marine component: natural amino acids, fatty acids and their glycosyl derivatives, sterols, natural antimicrobials, ursolic acid, or mono /
polysaccharides.
polysaccharides.
89. The composition of any one of claims 5-88, wherein the composition includes an amount of an anti-inflammatory agent.
90. The composition of claim 89, wherein the anti-inflammatory agent is Glycyrrhiza glabria, Boswellia serrate, Curcuma longa, turmeric, Arnica montana, silymarin, water melon, calendula, eidelweiss, or ginger.
91. The composition of any one of claims 5-90, wherein the composition includes an amount of a surfactant.
92. The composition of claim 91, wherein the surfactant is amphoteric.
93. The composition of claim 92, wherein the surfactant is cocomidopropyl betaine.
94. The composition of claim 91, wherein the surfactant is non-ionic.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
95. The composition of claim 94, wherein the surfactant is cocoglucoside or coco polyglucose.
96. The composition of claim 91, wherein the surfactant is cationic.
97. The composition of claim 96, wherein the surfactant is lauryl dimoniumhydrolysed collagen.
98. The composition of any one of claims 5-97, wherein the composition includes an amount of a percutaneous penetration enhancer.
99. The composition of claim 98, wherein the percutaneous penetration enhancer is polyethylene glycol or oleic acid.
100. The composition of any one of claims 5-99, wherein the composition includes an amount of a preservative enhancer.
101. The composition of claim 100, wherein the preservative enhancer is ethylhexyl glycerin, benzethonym chloride, or a hydantoin/PCB blend.
102. The composition of any one of claims 5-101, wherein the composition includes an amount of a vasodilator.
103. The composition of claim 102, wherein the vasodilator is adenosine triphosphate or liposomal 1 arginine.
104. The composition of any one of claims 5-103, wherein the composition includes an amount of a vasoconstrictor.
105. The composition of claim 104, wherein the vasoconstrictor is sea buckthorn, milk thistle, or marshmallow root.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
106. The composition of any one of claims 5-105, wherein the composition includes an amount of a whitening agent.
107. The composition of any one of claims 5-106, wherein the composition includes an amount of a tyrosinase inhibitor.
108. The composition of claim 107, wherein the tyrosinase inhibitor is selected from the Glycyrrhiza species.
109. The composition of claim 107, wherein the tyrosinase inhibitor is a favnoid, a polyphenol, an isoflavon, or a coumarin.
110. The composition of any one of claims 5-109, wherein the composition includes an amount of octadecnedioic acid.
111. The composition of any one of claims 5-110, wherein the composition includes an amount of chalcones.
112. The composition of any one of claims 5-111, wherein the composition is absorbed by human skin.
113. The composition of any one of claims 5-112, wherein the composition is homogeneous.
Date Recue/Date Received 2021-09-02
Date Recue/Date Received 2021-09-02
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3129790A CA3129790A1 (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2701378A CA2701378C (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
CA3129790A CA3129790A1 (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2701378A Division CA2701378C (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3129790A1 true CA3129790A1 (en) | 2011-10-22 |
Family
ID=44834913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2701378A Active CA2701378C (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
CA3129790A Abandoned CA3129790A1 (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2701378A Active CA2701378C (en) | 2010-04-22 | 2010-04-22 | Seaweed-derived cosmetic compositions |
Country Status (1)
Country | Link |
---|---|
CA (2) | CA2701378C (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2934104C (en) * | 2013-12-23 | 2022-09-27 | Medical Brands Research B.V. | Dermatological composition based on algae and olive leaf extracts |
FR3021870B1 (en) * | 2014-06-06 | 2017-10-27 | Espa Sa-Experts In Science & Product Achievements | DERMATOLOGICAL COMPOSITION BASED ON NIACINAMIDE |
BR112017012648B1 (en) | 2014-12-22 | 2020-12-08 | Unilever N.V | oral or topical composition and use of an erythroid nuclear factor 2 agonist related to factor 2 and a liver x receptor agonist as active agents in an oral or topical composition to benefit the growth of hair fiber and / or induce the antioxidant response element (are) |
PL3280423T3 (en) * | 2015-04-08 | 2023-12-27 | Microvascular Health Solutions, LLC | Synergistic glycocalyx treatment compositions and methods |
CN106074205A (en) * | 2016-04-18 | 2016-11-09 | 山东理工大学 | The application in whitening product of a kind of genistein benzylpiperazine derivative |
CN105832633A (en) * | 2016-04-28 | 2016-08-10 | 福建春伦茶业集团有限公司 | Moisturizing and skin whitening mask for restraining melanin forming |
WO2018222902A1 (en) | 2017-06-02 | 2018-12-06 | Extreme Fire Solutions, Llc | Fire extinguishing systems and compositions and methods of use thereof |
CN107638341A (en) * | 2017-08-25 | 2018-01-30 | 广州仙施生物科技有限公司 | A kind of amino acid cleansing cream and preparation method thereof |
CN108013036B (en) * | 2017-12-12 | 2020-08-18 | 深圳大学 | Application and preparation method of pyrrole-2-carboxylic acid |
US11116220B2 (en) | 2017-12-22 | 2021-09-14 | Ecolab Usa Inc. | Antimicrobial compositions with enhanced efficacy |
CN108992359A (en) * | 2018-09-20 | 2018-12-14 | 梅淑婕 | A kind of preparation method of skin care compositions and facial mask with whitening effect |
WO2020122941A1 (en) | 2018-12-14 | 2020-06-18 | Colgate-Palmolive Company | Silicone free emulsion-based personal care compositions and methods for the same |
CN109513011A (en) * | 2018-12-25 | 2019-03-26 | 福州大学 | A kind of preparation method and applications of the self-assembled nanometer grain with target function |
AU2019472201B2 (en) * | 2019-11-01 | 2024-05-02 | Colgate-Palmolive Company | Stable low pH personal care compositions and methods for the same |
CN111944165B (en) * | 2020-07-15 | 2022-04-01 | 汕头大学 | Polyphenol tyrosinase inhibitor and extraction method and application thereof |
IT202000014953A1 (en) * | 2020-09-03 | 2022-03-03 | Lacote S R L | COSMETIC COMPOUND |
CN117965247B (en) * | 2024-01-30 | 2024-07-30 | 东莞市建文洗涤用品有限公司 | Strong-effect antibacterial laundry detergent and preparation method thereof |
-
2010
- 2010-04-22 CA CA2701378A patent/CA2701378C/en active Active
- 2010-04-22 CA CA3129790A patent/CA3129790A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2701378C (en) | 2022-11-01 |
CA2701378A1 (en) | 2011-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11260014B2 (en) | Seaweed-derived cosmetic compositions | |
CA2701378C (en) | Seaweed-derived cosmetic compositions | |
ES2421262T3 (en) | Composition for personal and cosmetic care containing tetrapeptides with CX1X2G, PX1X2P or PX1X2K units | |
US20050209130A1 (en) | Compositions and methods for treatment of rosacea | |
ES2903108T3 (en) | Compositions and methods of stimulation of stem cells | |
CN108125803A (en) | A kind of whitening spot-eliminating composition | |
US20230117640A1 (en) | Putrescine topical formulations | |
EP1866036A2 (en) | Methods and compositions for preventing and treating aging or photodamaged skin | |
WO2020033450A1 (en) | Wrinkle reducing compositions and methods | |
CN107365355A (en) | The peptide of anti-wrinkle and the cosmetics for including it | |
US20220401339A1 (en) | Seaweed-derived cosmetic compositions | |
JP5455292B2 (en) | Skin external composition | |
JP2020033346A (en) | Topical composition containing pichia anomala and n-acetylglucosamine | |
JP5986416B2 (en) | Skin preparation | |
JP7343885B2 (en) | skin cosmetics | |
US20240130948A1 (en) | Compositions and methods for improving the appearance of the skin | |
JP2019069919A (en) | Gelatinous composition | |
RU2806599C1 (en) | Cosmetic composition with anti-aging activity to prevent aging and correct age-related changes in skin, its use (options) | |
KR20100033729A (en) | A cosmetic composition containing n-acetylglucosamine and vitamin c | |
JP5137326B2 (en) | Topical skin preparation | |
US20150030548A1 (en) | External preparation for skin | |
JP2022166655A (en) | Skin cosmetic | |
US20230321006A1 (en) | Putrescine topical barrier formulation | |
JP2023068570A (en) | Skin external preparation | |
JP2023044274A (en) | Topical skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20211112 |
|
EEER | Examination request |
Effective date: 20211112 |
|
EEER | Examination request |
Effective date: 20211112 |
|
EEER | Examination request |
Effective date: 20211112 |
|
EEER | Examination request |
Effective date: 20211112 |
|
FZDE | Discontinued |
Effective date: 20240412 |